



Long-term prediction of major coronary or ischemic stroke event in a low-incidence European population: model development and evaluation of clinical utility

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003630
Article Type:	Research
Date Submitted by the Author:	20-Jul-2013
Complete List of Authors:	Veronesi, Giovanni; Università degli Studi dell'Insubria, Dipartimento di Medicina Clinica e Sperimentale Gianfagna, Francesco; Università degli Studi dell'Insubria, Dipartimento di Medicina Clinica e Sperimentale Chambless, Lloyd; University of North Carolina at Chapel Hill, Biostatistics Giampaoli, Simona; Istituto Superiore di Sanità, Mancia, Guiseppe; Università di MILano-Bicocca, Dipartimento di medicina clinica e prevenzione Cesana, Giancarlo; Università di MILano-Bicocca, Dipartimento di medicina clinica e prevenzione Ferrario, Marco; Università degli Studi dell'Insubria, Dipartimento di Medicina Clinica e Sperimentale
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	Cardiac Epidemiology < CARDIOLOGY, Ischaemic heart disease < CARDIOLOGY, PREVENTIVE MEDICINE

SCHOLARONE™
Manuscripts

1
2
3
4 **Long-term prediction of major coronary or ischemic stroke event in a low-incidence**
5 **European population: model development and evaluation of clinical utility**
6
7

8
9 **Short Title: Clinical utility of long-term CVD risk prediction in primary prevention**
10

11
12 Giovanni Veronesi¹, Francesco Gianfagna¹, Lloyd E Chambless², Simona Giampaoli³,
13 Giuseppe Mancia⁴, Giancarlo Cesana⁴, and Marco M Ferrario¹.
14

- 15
16
17 1. Research Centre in Epidemiology and Preventive Medicine, Department of Clinical and
18 Experimental Medicine. University of Insubria, Varese, Italy.
19 2. Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC,
20 USA
21 3. Istituto Superiore di Sanità, Roma, Italy
22 4. Department of Clinical Medicine, Prevention and Health Biotechnology, University of
23 Milano-Bicocca, Milano, Italy
24
25
26
27
28
29
30
31
32
33

34 Corresponding author:
35

36 Dr Giovanni Veronesi
37 Research Centre in Epidemiology and Preventive Medicine
38 University of Insubria
39 Via O Rossi, 9 - Padiglione Rossi, I piano
40 I-21100 Varese, Italy
41 Phone +39-0332-270696
42 Fax +39-0332-278986
43 giovanni.veronesi@uninsubria.it
44
45
46
47
48
49

50 **Key words:** long-term risk, prediction, cardiovascular disease, clinical utility, primary
51 prevention
52

53 **Word count: 2908**
54
55
56
57
58
59
60

ARTICLE SUMMARY

Article focus

- Primary prevention of cardiovascular disease (CVD) has been recently moved towards the concepts of “lifetime” and “long-term” risk, especially in young subjects and women.
- There is no long-term risk prediction model available for European populations; in addition, the evaluation of the clinical benefit of long-term prediction has not been provided so far.
- We aim to develop a 20-year risk score equation in a northern Italian population of men and women considered at low incidence of major cardiovascular events; and to evaluate the clinical utility of the model for risk stratification in primary CVD prevention program.

Key Messages

- In our population, the 20-year risk model had satisfactory discrimination ability as compared to short-term risk prediction. The importance of long-term prediction for early identification of young subjects and women at increased likelihood of event during their remaining lifespan is confirmed.
- Risk stratification based on the predicted 20-year risk had a better clinical Net Benefit with respect to a stratification based on the number of risk factors, in men and women.
- In both genders, the optimal treatment allocation based on 20-year risk can be determined according to different public health strategies, i.e. either to reduce the fraction of events potentially un-prevented or to avoid un-necessary treatment.

Strengths and limitations of this study

- Our sample comprises subjects drawn from a representative northern Italian population, with a satisfactory participation rate. We also mention the high-quality of follow-up

1
2
3
4 procedures, including case ascertainment for non-fatal events and a consistent event
5
6 validation according to MONICA criteria over the whole follow-up period.
7

- 8
9 ■ Our 20-year risk prediction model is the first attempt to characterize long-term risk of
10
11 first coronary or ischemic stroke event in a low-incidence European population. To allow
12
13 applying our equation to different populations, as Supplementary Material we provide the
14
15 baseline survival term as well as the calibration slope. However, an external validation
16
17 study might be desirable. We also remind that our underlying population is characterized
18
19 by high levels of industrialization and urbanization, with one of the highest average
20
21 incomes in Italy. Caution is therefore required before generalizing our findings to
22
23 different contexts.
24
25
26
27

28 29 **ABSTRACT**

30
31
32 **Objective.** To develop a long-term prediction model of first major cardiovascular event and
33
34 to assess its clinical utility in a low-incidence European population.
35

36
37 **Setting.** Four independent population-based cohorts enrolled between 1986 and 1993 in
38
39 Northern Italy.
40

41
42 **Participants and methods.** N=5,247 35-69 years old men and women free of cardiovascular
43
44 disease at baseline. Absolute 20-year risk of first fatal or non-fatal coronary or ischemic
45
46 stroke event (MONICA validated) was estimated from gender-specific Cox models.
47

48
49 **Main outcome measures.** Model discrimination (Area Under the ROC-Curve, AUC). “High-
50
51 risk” subjects were defined based on several threshold values for the 20-year predicted risk.
52
53 Clinical utility was defined in terms of fraction of missed events (events among those
54
55
56
57
58
59
60

1
2
3
4 considered at low-risk) and unnecessary treatment (false:true positives ratio). A Net Benefit
5
6 curve was also provided.
7

8 **Results.** Kaplan-Meier 20-year risk was 16.1% in men (315 events) and 6.1% in women (123
9
10 events). Model discrimination (AUC=0.737 in men, 0.801 in women) did not change
11
12 significantly as compared to 10-year prediction time interval. In men, with respect to risk
13
14 stratification based on the number of risk factors, a 20% predicted risk cut-off would miss
15
16 less events (36% vs. 50%) and reduce unnecessary treatment (false:true positive ratio: 2.2 vs.
17
18 3.0); the Net Benefit was higher over the whole range of threshold values. Similar
19
20 considerations hold for women.
21
22

23
24 **Conclusions.** Long-term prediction has good discrimination ability and is clinically useful for
25
26 risk stratification in primary prevention. A clinical utility analysis is recommended to identify
27
28 the optimal stratification according to different public health goals.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Current European and American guidelines for primary prevention of major coronary and stroke events recommend the use of a multivariable risk prediction method to identify high risk subjects [1, 2]. Several risk scores are available in different US [3, 4] and European [5] populations of middle-aged adults, including the Italian one [6], to estimate the risk of first fatal and non-fatal cardiovascular event over a 10 year time interval. Primary prevention however has been recently moved towards the concepts of “lifetime” [7] and “long-term” risks [8], motivated also by the increasing life expectancy in western Countries. To this extent, 10-year risk prediction models are inadequate to distinguish between those at both low short-term and long-term risks, and those at low short-term but at elevated long-term risk due to the presence of non-optimal risk factors levels [9-11]. In the Framingham Study population, an unfavorable risk factor profile led to an increased 30-year risk of first cardiovascular event, independently on the age at the risk factors assessment [10]. In a representative sample of the Italian population, about 80% of individuals classified at low 10-year risk had increased lifetime risk according to US definition ($\geq 40\%$), potentially leading to a consistent number of un-prevented events that might have been prevented if lifetime risk had been considered [11]. This group was largely composed of women and young subjects, suggesting that long-term prediction models for risk stratification may be even more beneficial in populations at low incidence of cardiovascular disease [12]. To this extent, the development of a specific long-term risk prediction should be preferred with respect to re-calibration of risk models derived in high-incidence countries [13]. However, extending the range of risk prediction is not a straightforward operation. Although several studies have shown that a single measurement of risk factor is predictive of future events after 30 plus years [10, 14], behavioral changes and risk factors modification may affect model

1
2
3
4 discrimination. High-quality follow-up data, with a consistent event definition and validation
5
6 over-time, are also required. Finally, subjects' stratification in risk categories is often based
7
8 on arbitrary cut-points of absolute risk [15] which may show no benefit in clinical practice
9
10 [16]. The evaluation of the clinical benefit of long-term prediction by means of some
11
12 standard measure [17] has not been provided so far and is therefore required [8].

13
14 The aim of the present paper is to develop a 20-year risk score equation in a European
15
16 population of men and women considered at low incidence of major cardiovascular events. In
17
18 addition to standard model calibration and discrimination tools, we evaluate the clinical
19
20 utility of the model for risk stratification.
21
22
23

24 **METHODS**

25 **Study population**

26
27 The Brianza population comprises residents in 173 municipalities in the area between Milan
28
29 and the Swiss border, Northern Italy. The CAMUNI study includes four independent
30
31 population surveys carried out between 1986 and 1994 as part of either the WHO-MONICA
32
33 Project[3 surveys; 18] or the PAMELA study [19]. Participation rates were 70.1%, 67.2%,
34
35 and 70.8% for the three MONICA surveys, respectively, and 64% for the PAMELA Study,
36
37 with no differences between men and women. Both the baseline screening and the follow-up
38
39 for all the surveys were approved by the ethical committee of the Monza Hospital.
40
41
42
43

44 **Baseline assessment of risk factors**

45
46 Cardiovascular risk factors were collected at baseline strictly adhering to the standardized
47
48 procedures and quality standards of the WHO-MONICA Project [20]. Height and weight
49
50 were measured on subjects without shoes and wearing light clothing. Trained technicians
51
52 collected blood pressure at right arm on subjects in sitting position and at rest, using a
53
54 standard mercury sphygmomanometer equipped with two side cuff bladders, for normal and
55
56
57
58
59
60

1
2
3
4 obese subjects. Systolic and diastolic blood pressure were assessed twice, at 5 minutes apart,
5
6 recording the first and fifth phase of the Korotkoff sounds. The study variable for systolic
7
8 blood pressure is the average of the two measurements. Venous blood specimens were taken
9
10 from the ante-cubital vein on fasting subjects (12 hours or more). Serum total cholesterol,
11
12 HDL-cholesterol and blood glucose were determined using the enzymatic methods; HDL-
13
14 cholesterol fraction was separated using the Phosphotungstate-Mg⁺⁺ method [20]. A
15
16 standardized interview was administered to participants by trained interviewers. Information
17
18 on the use of anti-hypertensive treatment in the last two weeks was dichotomised as yes/no;
19
20 similarly, cigarette smoking habit was dichotomised as current versus past/never smokers.
21
22 Diabetes mellitus was defined using self-reported diagnoses, information on insulin and oral
23
24 hypoglycaemic treatments and fasting blood glucose exceeding 7 mmol/L (126 mg/dl). The
25
26 presence at baseline of a previous history of MI, unstable angina pectoris, cardiac
27
28 revascularization or stroke was defined based on self-reported information.
29
30
31
32

33 **Study endpoint and follow-up procedures**

34
35 The study endpoint is defined as the occurrence of first major coronary event (myocardial
36
37 infarction, acute coronary syndrome and coronary revascularization) as well as for first
38
39 ischemic stroke or carotid endarterectomy, fatal and non-fatal [13]. Data completeness for
40
41 fatal events was assured through a systematic collection of death certificates provided by
42
43 local health units; vital status and death certificates were available for 99% of the subjects.
44
45 Suspected out-of-hospital deaths were investigated through interview of relatives. Suspected
46
47 hospitalized coronary (discharge code ICD-IX 410 or 411 and ICD-IX CM 36.0-9 for
48
49 coronary revascularization) and stroke events (ICD-IX 430-432, 434, 436; ICD-IX CM
50
51 38.01-39.22 or 39.50-39.52 with at least one 430-438 as discharge code, for carotid
52
53 endarterectomy) were identified through deterministic and probabilistic record linkages with
54
55
56
57
58
59
60

1
2
3
4 regional hospital discharge databases, obtaining a satisfactory performance in case finding, as
5 reported [18, 21]. All acute events were investigated and validated according to the MONICA
6 diagnostic criteria [20]; the ischemic subtype for stroke was attributed after review of the
7
8 available clinical information.
9
10

11 12 13 **Statistical analysis**

14
15 The CUORE Project 10-year risk equation for the Italian population [6, 18] constituted the
16
17 base for the development of the 20-year risk prediction model. We considered gender-
18
19 specific Cox regression models with age, total cholesterol, HDL-cholesterol, systolic blood
20
21 pressure, anti-hypertensive treatment, cigarette smoking and diabetes. After a preliminary
22
23 check on linearity, total- and HDL-cholesterol were included in the model as categorical
24
25 variables in four standard classes [4, 22]. The interaction between systolic blood pressure and
26
27 anti-hypertensive treatment was not statistically significant (p-value 0.84 in men and 0.12 in
28
29 women, respectively). Finally, no violations in the proportional hazard assumption were
30
31 observed using a standard test for time-dependent variables.
32
33

34
35 Model calibration was assessed through the Grønnesby-Bogan goodness-of-fit test [23]. The
36
37 Area Under the ROC-curve (AUC), as well as sensitivity and specificity in the top and
38
39 bottom predicted risk quintiles, were computed taking censorship into account [24].
40

41
42 Correction for over-optimism and confidence intervals for the AUC were obtained through
43
44 1000 bootstrapped samples [25]. To assess the hypothesis of a loss in discrimination ability
45
46 due to a longer prediction period, we estimated the 10-year predicted probability of event in
47
48 our database, using the same set of risk factors but with shorter follow-up period, i.e. up to
49
50 the end of 2002 for all the subjects. We then compared the AUC of both models, by
51
52 considering bootstrapped confidence intervals for the difference in the betas.
53
54
55
56
57
58
59
60

1
2
3
4 To assess the clinical utility of the long-term model for risk stratification, we considered two
5
6 different public health goals. One is to decrease the number of events occurring among those
7
8 considered at “low-risk”. If we assume that a subject classified at “high risk” will be targeted
9
10 for prevention (either lifestyle intervention or treatment), any event occurring outside this
11
12 category is “not-identified” or “missed” by the prevention strategy. The second strategy aims
13
14 instead to reduce un-necessary treatment, by decreasing the number of non-events among
15
16 those considered at “high-risk”. Under the two scenarios, “high-risk” subjects are defined as
17
18 those with predicted risk above a certain cut-off value. Clinical utility is defined in terms of
19
20 *i)* fraction of “missed” events; *ii)* probability of event among those classified at high risk; and
21
22 *iii)* false positive/true positive ratio, for several threshold values in the 20-year predicted risk.
23
24 We also provide a decision curve analysis based on the net benefit: Net Benefit = (true
25
26 positives - w*false positives)/n, where n is the sample size and the weight w represents the
27
28 ratio between the harm of un-necessary treatment and the harm of missing a case at that given
29
30 value of predicted risk [17]. All the analyses were conducted using the SAS software 9.2.
31
32
33
34

35 RESULTS

36
37 N=5,426 (2,703 men) subjects were enrolled in the age range 35-69 years. N=205 subjects
38
39 (3.8%; n=14 events) had at least one missing data; we considered data imputation (R
40
41 *transcan* function, [26]) and excluded only those with missing values in more than 4
42
43 covariates of interest (n=6 men and n=3 women). Finally n=120 men and n=45 women with a
44
45 positive history of CVD at baseline were also excluded, reducing the sample size to 2,574
46
47 men and 2,673 women.
48
49

50
51 Baseline characteristics of the study population, by gender, are shown in **Table 1**. During a
52
53 median follow-up time of 15 years (interquartile range: 12-20), we observed 315 first CVD
54
55
56
57
58
59
60

1
2
3
4 events in men (233 coronary events) and 123 in women (n=85 coronary events). The Kaplan-
5
6 Meier estimate for 20-year risk was 16.1% and 6.1% in men and women, respectively.
7
8

9 **Model development**

10
11 The beta-coefficients for the 20-year risk prediction model, as well as the baseline survival
12
13 term and the calibration slope [25], are provided in the Supplementary Material (**Table S1**).
14

15 All the risk factors were statistically significant, except for anti-hypertensive treatment,
16
17 though its point estimate reflected a 30% increase in hazard in both men and women; the
18
19 variable was retained in the model for comparability with the short-term CUORE model [6].
20
21 There were no significant differences in the set of beta estimates for the 20-year model as
22
23 compared to those from the 10-year risk model for the risk factors in the model (data not
24
25 shown). The model calibration was satisfactory, in men (Grønnesby-Bogan goodness-of-fit
26
27 chi-square 6.7, p-value 0.67) and in women (chi-square 9.6, p-value 0.38).
28
29

30
31 We found no statistically significant difference in the overall discrimination ability between
32
33 long- and short-term prediction models, in men (0.736 vs. 0.731) and in women (0.801 vs.
34
35 0.816; **Table 2**). Only 5% of 20-year events in men occurred among subjects with a predicted
36
37 risk below the 20th percentile (bottom quintile); the corresponding figure in women is 2%.
38

39
40 The relative risk of event for being above the 80th percentile vs. below the 20th percentile of
41
42 20-year risk was 9.5 (i.e. 35.1/3.7) in men and 22.4 (i.e. 20.2/0.9) in women. Finally, the
43
44 value of the 80th percentile for 20-year risk was more than twice as high than the similar
45
46 percentile for 10-year risk in men (26.8 vs. 10.8) and more than three times as high in women
47
48 (10.1 vs. 3.0). A similar consideration holds for the 20th percentile of risk or the median
49
50 value.
51

52 **Clinical utility**

1
2
3
4 **Table 3a** and **Table 3b** describe strategies for the identification of high-risk subjects, based
5 on predicted 20-year risk, in men and women respectively. A cut-off value of 10% twenty
6 year risk in men would result in a 9% of “missed” events (i.e. events among those with
7 predicted risk below the cut-point), with a probability of event of 23% and one true positive
8 for every 3.4 false positive subjects (**Table 3a**). In the second scenario, by choosing the 20%
9 twenty year risk threshold value, the fraction of missed events was 36%. Note that about 30%
10 of events occurred for a predicted 20-year risk between 20% and 30%. Finally, using the
11 number of risk factors to define high risk subjects would result in a higher fraction of missed
12 events, with no changes in specificity or in the prevalence of subjects considered at high risk.
13 Among women, a cut-off value of 2% would result in a 5% of missed events, with a
14 probability of event of 9% and a true positive for every 10.1 false positive women (**Table**
15 **3b**). In the second scenario, the probability of event among those with absolute risk greater
16 than 10% was 20.4%, with a true positive for every 3.9 false positive subjects. However, the
17 fraction of missed events would be 32%; this number can be reduced by lowering the cut-off
18 value to 8%. By considering at high risk those with 2 or more risk factor would result in a
19 higher fraction of missed events, with no gain in specificity or in the probability of event in
20 the group. **Figure 1** illustrates the decision curve analysis based on the Net Benefit [17], for
21 men (left) and women (right). The figure suggests a greater net benefit for the predicted risk
22 with respect to the number of risk factors over the whole range of values, thus generalizing
23 the findings from Table 3a and Table 3b.

48 **DISCUSSION**

49
50 In this paper we present the 20-year prediction model of first major coronary or ischemic
51 stroke event in a Northern Italian population of men and women aged 35 to 69 years at
52 baseline. To our knowledge, this is the first long-term prediction model in a low-incidence,
53
54
55
56
57
58
59
60

1
2
3
4 European population. The discrimination ability of the long-term model did not significantly
5 drop with respect to a 10-year risk prediction model derived on the same population. Risk
6 stratification based on the predicted 20-year risk can be modulated according to different
7 prevention aims, i.e. either to reduce the fraction of events potentially un-prevented or to
8 avoid un-necessary treatment. Under both scenarios, the predicted 20-year risk showed an
9 overall better Net Benefit with respect to a risk stratification based on the number of risk
10 factors.

11
12 Our data confirmed previous findings on predictiveness of a single measurement of risk
13 factors on long-term CVD risk, in the Italian [27] as well as in other populations [10, 14].
14 Event discrimination for the 20-year risk prediction model did not change significantly from
15 10-year's, although in women it decreased from 0.814 to 0.801. In the Framingham Offspring
16 Study updating the baseline measurement of blood pressure and lipids with a later assessment
17 poorly affected model discrimination and reclassification [28] and cardiometabolic risk
18 factors clustering has been found to be quite stable over time [29].

19
20 As in the Framingham population, in our study the long-term predicted risk was more than
21 simply n -times the short-term risk prediction [10]. In addition in the age range 35 to 49
22 years, the long-term predicted risk in subjects with 1 or more non-optimal or elevated risk
23 factors (defined as in [7]) was 3-times the short-term risk in men, and 4-times in women (see
24 **Figure S1** in the Supplementary Material). This conveys the importance of long-term
25 prediction for early identification of young subjects and women at increased likelihood of
26 event during their remaining lifespan. We observed in our data a modest net reclassification
27 improvement (computed as in [24]) for the 20-year risk prediction model over the re-
28 calibrated 10-year risk, in men (1.8%) and in women (4.5%). The net reclassification
29 increased when we considered subjects with a low 10-year predicted risk but a cluster of 2 or
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 more risk factors (5.4% and 7.6% in men and women, respectively; data not shown).
5
6
7 Subjects' stratification is often based on arbitrarily-chosen thresholds of predicted risk [15],
8
9 which may limit the clinical utility of risk prediction models [16]. We considered two
10
11 strategies for the identification of "high-risk" subjects with contrasting goals, either to
12
13 decrease the fraction of missed events or to decrease un-necessary treatment. These can be
14
15 implemented by choosing threshold values for the predicted risk driven by either sensitivity
16
17 or by specificity, respectively. Despite the lowering costs of statin treatment with respect to
18
19 the costs of one un-prevented event, the high sensitivity scenario might not be cost-effective
20
21 [30]. These two scenarios might be combined to adopt a more complex risk stratification, as
22
23 often present in clinical practice [1-2, 12]. For instance, if we consider at "low-risk" the 36%
24
25 of men with 20-year absolute risk less than 10%, the fraction of missed events would be 9%,
26
27 i.e. 31 first events in 20 years. About 31% of men with absolute risk between 10% and 20%
28
29 could be addressed for lifestyle modification or treatment according to the presence of
30
31 specific risk factors; this category accounts for about 20% of cases. Finally, the 33% of men
32
33 with predicted risk above the 20% could be targeted with treatment intervention; they account
34
35 for 68% of events, and out of 3.2 treated men, one is a case. A similar stratification can be
36
37 provided for women, with different threshold values reflecting gender-specific underlying
38
39 risk as for the cardiovascular age assessment [15].
40
41
42
43

44 Among the study strengths and limitations, our sample comprises subjects drawn from a
45
46 representative northern Italian population, with a satisfactory participation rate. The
47
48 underlying population is characterized by high levels of industrialization and urbanization,
49
50 with one of the highest average incomes in Italy. As Supplementary Material we provide the
51
52 baseline survival term as well as a calibration slope [25] to allow applying our equation to
53
54 different contexts. However, a validation study in a different population might be desirable to
55
56
57
58
59
60

1
2
3
4 investigate the generalizability of our findings. We also mention a high-quality of follow-up
5
6 procedures, including case ascertainment for non-fatal events [21] and a consistent event
7
8 validation according to MONICA criteria, resulting in a Standardized Incidence Rate for the
9
10 study cohorts above 1 over the whole follow-up period [18]. Finally, the study endpoint
11
12 reflects the clinical need to treat the “global” ischemic risk of a given patient, and not its
13
14 separate components [3].
15

16
17
18 In conclusions, we provide a model to predict long-term risk of first major ischemic
19
20 cardiovascular event in a low-incidence population. Risk stratification based on long-term
21
22 risk can be clinically useful, especially for young subjects and women. A clinical utility
23
24 analysis is required to identify the optimal stratification, according to different public health
25
26 goals.
27

28 29 30 31 **Funding**

32
33 This work was supported by grants from the Health Administration of Regione Lombardia
34
35 [grant number 10800/2009], as part of the Osservatorio Epidemiologico Cardiovascolare
36
37 Regionale Lombardo.
38

39 40 **Competing Interests**

41
42 None.
43

44 45 **Contributors**

46
47 Conception and design: MMF, GM, GC and GV. All authors interpreted the data and
48
49 critically reviewed the paper. Statistical analyses: GV, WC. GV drafted the manuscript and is
50
51 the guarantor. All authors have read and approved the final version of the manuscript.
52

53 54 **Data sharing**

55
56 There is no additional data available
57
58
59
60

REFERENCES

1. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). *Eur Heart J* 2012;33:1635-1701
2. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update : Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. *Circulation* 2002;106:388-391
3. D'Agostino RB, Ramachandran SV, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care. The Framingham Heart Study. *Circulation* 2008;117:743-753
4. Chambless LE, Folsom AR, Sharrett AR, Sorlie P, Couper D, Szklo M, Nieto FJ. Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. *J Clin Epidemiol.* 2003;56:880-90
5. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal Cardiovascular disease in Europe: the SCORE project. *Eur Heart J* 2003;24:987-1003
6. Palmieri L, Panico S, Vanuzzo D, Ferrario M, Pilotto L, Segna R, Cesana G, Giampaoli S per il gruppo di ricerca del Progetto CUORE. Evaluation of the global cardiovascular absolute risk: the Progetto CUORE individual score. *Ann Ist Super Sanità* 2004;40:393-399.
7. Lloyd-Jones DM, Leip EP, Larson MG, D'Agostino RB, Beiser A, Wilson PWF, Wolf P, Levy D. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. *Circulation* 2006;113:791-798
8. Lloyd-Jones DM. Short-term versus long-term risk for coronary artery disease: implications for lipid guidelines. *Curr Opin Lipidol* 2006;17:619-625
9. Daviglius ML, Stamler J, Pirzada A, Yan LL, Garside DB, Liu K, Wang R, Dyer AR, Lloyd-Jones DM, Greenland P. Favourable cardiovascular risk profile in young women and long-term risk of cardiovascular and all-cause mortality. *JAMA* 2004;292:1588-1592
10. Pencina MJ, D'Agostino RB, Larson MG, Massaro JM, Vasan RS. Predicting the 30-year risk of cardiovascular disease. The Framingham Heart Study. *Circulation* 2009;119:3078-3084
11. Di Castelnuovo A, Costanzo S, Persichillo M, Olivieri M, de Curtis A, Zito F, Donati MB, de Gaetano G, Iacoviello L. Distribution of short and lifetime risks for cardiovascular disease in Italians. *Eur J Prev Cardiol* 2011;19:723-730.

- 1
2
3
4
5
6
7
8 12. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, et al. Effectiveness-
9 based guidelines for the prevention of cardiovascular disease in women—2011 update: a
10 guideline from the American Heart Association. *J Am Coll Cardiol* 2011;57:1404–1423
11
- 12 13. Ferrario MM, Chiodini P, Chambless LE, Cesana G, Vanuzzo D, Panico S, Sega R,
13 Pilotto L, Palmieri L and Giampaoli S for the CUORE Project Research Group. Prediction of
14 coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort
15 Study prediction equation. *Int J Epidemiol* 2005;34:413-21
16
- 17 14. Menotti A, Lanti M, Kafatos A, Nissinen A, Dontas A, Nedeljkovic S, Kromhout D, for
18 the Seven Countries Study. The role of baseline casual blood pressure measurement and of
19 blood pressure changes in middle age in prediction of cardiovascular and all-cause mortality
20 occurring late in life: a cross-cultural comparison among the European cohorts of the Seven
21 Countries Study. *J Hypertens* 2004;22:1683-1690
22
- 23 15. Grover SA, Lowensteyn I. The challenges and benefits of cardiovascular risk assessment
24 in clinical practice. *Can J Cardiol* 2011;27:481-487
25
- 26 16. Collins GS, Altman DG. Predicting the 10 year risk of cardiovascular disease in the
27 United Kingdom: independent and external validation of an updated version of QRISK2.
28 *BMJ* 2012;344:e4181.
29
- 30 17. Vickers AJ, Cronin AM, Elkin EB, Gonen M. Extensions to decision curve analysis, a
31 novel method for evaluating diagnostic tests, prediction models and molecular markers. *Med
32 Decis Making* 2008;8:53
33
- 34 18. Ferrario M, Sega R, Chatenoud L, et al. Time trends of major coronary risk factors in a
35 northern Italian population (1986-1994). How remarkable are socio-economic differences in
36 an industrialised low CHD incidence country? *Int J Epidemiol* 2001;30:285-291.
37
- 38 19. Cesana GC, De Vito G, Ferrario M, et al. Ambulatory blood pressure normalcy: The
39 PAMELA Study. *J Hypertension Suppl* 1991;9:17-23.
40
- 41 20. WWW-publications from the WHO MONICA Project. MONICA Manual. Available at:
42 <http://www.thl.fi/publications/monica/manual/index.htm>.
43
- 44 21. Fornari C, Madotto F, Demaria M, Romanelli A, Pepe P, Raciti M, Tancioni V, Chini F,
45 Trerotoli P, Bartolomeo N, Serio G, Cesana G, Corrao G. Record-linkage procedures in
46 epidemiology: an Italian multicentre study. *Epidemiol Prev* 2008;32:79-88.
47
- 48 22. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannnel WB.
49 Prediction of coronary heart disease using risk factors category. *Circulation* 1998;97:1837-47
50
- 51 23. May S., Hosmer DW. A simplified method of calculating an overall Goodness-of-Fit test
52
53
54
55
56
57
58
59
60

1
2
3
4 for the Cox proportional hazards model. *Lifetime Data Anal* 1998;4:109-120
5
6

7
8 24. Chambless LE, Cummiskey CP, and Cui G. Several methods to assess improvement in
9 risk prediction models: extension to survival analysis. *Statist med* 2011;30:22–28
10

11 25. Harrel FE, Lee KL and Marck DB. Tutorial in biostatistics: multivariable prognostic
12 models: issues in developing models, evaluating assumptions and adequacy, and measuring
13 and reducing errors. *Statist med* 1996;15:361–387
14

15 26. Harrel FE. R reference manual: Package ‘Hmisc’. Available at
16 <http://cran.r-project.org/web/packages/Hmisc/Hmisc.pdf>
17

18 27. Menotti A, Lanti M. Coronary risk factors predicting early and late coronary events.
19 *Heart* 2003;89:19-24
20

21 28. Bell K, Hayen A, McGeechan K, Neal B, Irwig L. Effects of additional blood pressure
22 and lipids measurements on the prediction of cardiovascular risk. *Eur J Prev Cardiol*
23 2012;19:1474-85
24
25

26 29. Camhi SM, Katzmarzyk PT. Tracking of cardiometabolic risk factor clustering from
27 childhood to adulthood. *Int J Pediatr Obes* 2010;5:122-129
28

29 30. Greving JP, Visseren FLJ, de Wit GA, Algra A. Statin treatment for primary prevention
30 of vascular disease: whom to treat? Cost-effectiveness analysis. *BMJ* 2011;342:d1672.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Tables and figures

Table 1. Baseline characteristics (mean (SD) or %) of the study population and number of incident events, by gender. Men and women, 35-69 years old, CVD-free at baseline.

	Men (n=2574)	Women (n=2673)
Age (years)	50.8 (9.1)	50.3 (9)
Years of schooling	8.5 (4.2)	7.3 (3.4)
Total Cholesterol (mmol/L)	5.8 (1.1)	5.8 (1.1)
HDL-Cholesterol (mmol/L)	1.3 (0.3)	1.6 (0.4)
Body Mass Index (Kg/m ²)	26.2 (3.5)	25.6 (4.7)
Systolic Blood Pressure (mmHg)	134.8 (19.3)	131.6 (20.2)
Diastolic Blood Pressure (mmHg)	85.9 (10.6)	82.8 (10.8)
Anti-hypertensive treatment (%)	11.8	16.0
Fasting plasma glucose (mmol/L)	5.4 (1.3)	5.1 (1.2)
Diabetes (%)	6.7	4.0
Current smoker (%)	37.1	19.6
Incident coronary event (n)	233	85
Incident ischemic strokes (n)	99	43
Incident CVD event (n)	315	123
20-year absolute risk of CVD [^]	16.1	6.1

[^]: Kaplan-Meier estimate.

Table 2. Discrimination ability for the 10-year and the 20-year risk prediction models.
Men and women, 35-69 years old, CVD-free at baseline

	Men		Women	
	10-year risk	20-year risk	10-year risk	20-year risk
AUC (95% CI)	0.731 (0.702; 0.761)	0.737 (0.713; 0.764)	0.814 (0.779; 0.853)	0.801 (0.771; 0.833)
Subjects with predicted risk below the 20th percentile				
20th percentile of risk	2.3	6.3	0.3	1.1
Fraction of events* (%)	4.4	5.1	1.4	2.0
Probability of event in the group [^] (%)	0.8	3.7	0.2	0.9
Subjects with predicted risk above the 80th percentile				
80th percentile of risk	10.8	26.8	3.0	10.1
Sensitivity* (%)	49.9	45.6	68.7	62.0
Specificity (%)	82.4	85.5	81.1	83.1
Probability of event in the group [^] (%)	19.4	35.1	7.5	20.2

The Area Under the ROC-curve (AUC) was estimated taking censorship into account, and adjusting for over-optimism (n=1000 bootstrap).

*: Probability of belonging to the group, given that the subject is a case. [^]: Kaplan-Meier estimate of the probability of event in the group.

Table 3a. Identification of high risk subjects based on the 20-year risk prediction model with respect to the number of risk factors, according to strategies aiming to *i*) reducing the fraction of missed events; and *ii*) reducing un-necessary treatment. Men, 35-69 years old, CVD-free at baseline

	Subjects at high risk		Fraction of missed events (%)	Specificity (%)	Probability of event* (%)	FP/TP Ratio
	n	%				
Strategy a: reduce the fraction of missed events						
All subjects	2574	100.0	0.0	-	16.1	5.2
1+ Major Risk Factor [#]	1842	71.6	13.7	32.5	19.5	4.1
20-year absolute risk > 10%	1645	63.9	9.1	41.2	22.9	3.4
20-year absolute risk > 15%	1169	45.4	22.1	60.9	27.7	2.6
Strategy b: reduce un-necessary treatment						
2+ Major Risk Factors [#]	828	32.2	50.4	73.6	24.9	3.0
20-year absolute risk > 20%	841	32.7	35.7	73.7	31.7	2.2
20-year absolute risk > 30%	415	16.1	62.6	88.9	37.4	1.7

“Missed” events are events occurring among subjects not classified at “high risk”, i.e. with 20-year absolute risk (or a number of risk factors) below the cut-off point.

*: Kaplan-Meier estimate of the probability of event in the group (positive predicted value).

FP = Number of False Positives; TP = Number of True Positives

[#]: total cholesterol > 240 mg/dl; HDL-cholesterol < 40 [men] or < 50 [women] mg/dl; systolic blood pressure > 160 mmHg; smoking; diabetes

Table 3b. Identification of high risk subjects based on the 20-year risk prediction model with respect to the number of risk factors, according to strategies aiming to *i*) reducing the fraction of missed events; and *ii*) reducing un-necessary treatment. Women, 35-69 years old, CVD-free at baseline

	Subjects at high risk		Fraction of missed events (%)	Specificity (%)	Probability of event* (%)	FP/TP Ratio
	n	%				
Strategy a: reduce the fraction of missed events						
All subjects	2673	100.0	0.0	-	6.1	15.3
1+ Major Risk Factor [#]	1654	61.9	17.7	40.1	8.2	11.3
20-year absolute risk > 2%	1733	64.8	4.5	37.4	9.0	10.1
20-year absolute risk > 5%	1067	39.9	14.7	63.2	13.1	6.6
Strategy b: reduce un-necessary treatment						
2+ Major Risk Factors [#]	640	23.9	42.3	79.5	14.8	5.8
20-year absolute risk > 8%	698	26.1	22.7	77.1	18.2	4.5
20-year absolute risk > 10%	545	20.4	32.1	82.7	20.4	3.9

“Missed” events are events occurring among subjects not classified at “high risk”, i.e. with 20-year absolute risk (or a number of risk factors) below the cut-off point.

*: Kaplan-Meier estimate of the probability of event in the group (positive predicted value).

FP = Number of False Positives; TP = Number of True Positives

#: total cholesterol > 240 mg/dl; HDL-cholesterol < 40 [men] or < 50 [women] mg/dl; systolic blood pressure > 160 mmHg; smoking; diabetes

1
2
3
4
5 **Figure 1:** Decision curve for the 20-year risk prediction model in the CAMUNI population, Northern Italy.
6 Men (left) and women (right), 35 to 69 years old, free of CVD at baseline.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 Net Benefit: $(TP - w * FP) / n$, where TP = True Positive; FP = False Positive; $w = (\text{Absolute risk threshold}) / (1 - (\text{Absolute risk threshold}))$; n=sample size
36 Number of risk factors: total cholesterol >240 mg/dl; HDL-cholesterol <40 [men] or <50 [women] mg/dl; systolic blood pressure >160 mmHg; smoking; diabetes
37
38
39
40
41
42
43
44
45
46
47
48
49




Figure 1: Decision curve for the 20-year risk prediction model in the CAMUNI population, Northern Italy. Men (left) and women (right), 35 to 69 years old, free of CVD at baseline.

Net Benefit: $(TP - w \cdot FP) / n$, where TP = True Positive; FP = False Positive; $w = (\text{Absolute risk threshold}) / (1 - \text{Absolute risk threshold})$; $n = \text{sample size}$

Number of risk factors: total cholesterol > 240 mg/dl; HDL-cholesterol < 40 [men] or < 50 [women] mg/dl; systolic blood pressure > 160 mmHg; smoking; diabetes

180x119mm (300 x 300 DPI)

only

Supplementary material

Table S1: Beta-coefficients, standard errors and baseline survival for the 20-year risk prediction model in Northern Italy. Men and women, 35 to 69 years old, free of CVD at baseline.

	Men			Women		
	Beta	SE	p-value	Beta	SE	p-value
Age (years)	0.058	0.008	<.0001	0.084	0.014	<.0001
Total Cholesterol[^]						
200-240 mg/dl	0.388	0.161		0.553	0.287	
240-280 mg/dl	0.690	0.167	<.0001	0.607	0.310	0.027
> 280 mg/dl	0.923	0.198		0.996	0.328	
HDL-Cholesterol[°]						
<45 mg/dl	0.403	0.160		0.804	0.250	
45-50 mg/dl	0.367	0.186	0.013	0.364	0.309	0.015
50-60 mg/dl	0.024	0.177		0.261	0.225	
Systolic Blood Pressure (mmHg)	0.011	0.003	0.0003	0.015	0.005	0.001
Anti-hypertensive treatment (yes/no)	0.247	0.154	0.11	0.267	0.209	0.20
Smoking (yes/no)	0.521	0.117	<.0001	0.994	0.216	<.0001
Diabetes (yes/no)	0.744	0.163	<.0001	1.020	0.249	<.0001
Baseline 20-year survival (S₀(20))*		0.94168			0.98502	
G(μ)		4.35638			6.20915	
Calibration Slope		0.948			0.937	

SE = Standard Error. [^]: reference group: total cholesterol ≤ 200 mg/dl. [°]: reference group: HDL-cholesterol > 60 mg/dl. *: at the mean value for continuous RFs, and at the reference class for categorical variables. 20-year risk: $1 - S_0(20)^{\exp(\sum \beta X - G(\mu))}$.

Calibration slope: correction term that could be used in different population to shrink the beta-coefficients. See reference[25] for more details.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Figure S1: Distribution of predicted 10-year and 20-year risk of first major CVD event, according to the number of risk factors. Men (left) and women (right), 35 to 49 years old, free of CVD at baseline.

For peer review only

Risk factors stratification derived from Lloyd-Jones [7].
All optimal: total cholesterol <180 mg/dl, HDL-Cholesterol \geq 40 mg/dl [men] or \geq 50 mg/dl [women], blood pressure <120/80 mmHg, non smoker, non diabetic;
1+ non-optimal: total cholesterol 180 to 199 mg/dl, systolic blood pressure 120 to 139 mmHg, diastolic blood pressure 80 to 89 mmHg, non smoker, non diabetic
1+ elevated: total cholesterol 200 to 239 mg/dl, systolic blood pressure 140 to 159 mmHg, diastolic blood pressure 90 to 99 mmHg, non smoker, non diabetic
Major risk factor: total cholesterol \geq 240 mg/dl, HDL-Cholesterol <40 mg/dl [men] or <50 mg/dl [women], systolic blood pressure \geq 160 mmHg or treatment, diastolic blood pressure \geq 100 mmHg, smoker, or diabetic

1 **Supplementary material for the paper:**

2 **Long-term prediction of major coronary or ischemic stroke event in a low-incidence**

3 **European population: model development and evaluation of clinical utility.**

4 STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

5

6

7

8

9

	Item No	Recommendation	Actions
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	The study setting is clearly stated in the abstract.
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Done
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	See the introduction section at pages 3-4
Objectives	3	State specific objectives, including any prespecified hypotheses	See page 4, end of introduction section
Methods			
Study design	4	Present key elements of study design early in the paper	See the Methods section (pages 4-7)
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Relevant information on cohorts setting, location and periods of recruitment are provided in the paragraphs "Study population" (page 4), "Baseline assessment of risk factors" (page 4) and "Study endpoint and follow-up procedures" (page 5).
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	See the paragraphs "Study population" (page 4) and "Study endpoint and follow-up procedures" (page 5).
		(b) For matched studies, give matching criteria and number of exposed and unexposed	Not applicable
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	See the paragraph "Statistical analysis", page 6-7
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	See paragraphs "Baseline assessment of risk factors" (page 4), and "Statistical analysis" (page 6-7). Exposure group: not applicable for this analysis.
Bias	9	Describe any efforts to address potential sources of bias	See the Methods section.
Study size	10	Explain how the study size was arrived at	See the first period in the "Results" section (page 7)
Quantitative	11	Explain how quantitative variables were	See the "Statistical Analysis" paragraph

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

1	variables		handled in the analyses. If applicable, (page 6)
2			describe which groupings were chosen and
3			why
4	Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding
5			See the “Statistical Analysis” paragraph (page 6)
6			(b) Describe any methods used to examine subgroups and interactions
7			See the “Statistical Analysis” paragraph (page 6)
8			(c) Explain how missing data were addressed
9			See the first line in the “Results” section (page 7)
10			(d) If applicable, explain how loss to follow-up was addressed
11			See the “Statistical Analysis” paragraph (page 6) for details on the survival analysis techniques
12			(e) Describe any sensitivity analyses
13			Not applicable
14			
15			
16			
17	Results		
18	Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed
19			Participation rates are reported in the paragraph “Study population” (page 4). Exposure group: not applicable for this analysis.
20			(b) Give reasons for non-participation at each stage
21			Not applicable
22			(c) Consider use of a flow diagram
23			Not applicable
24	Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders
25			See Table 1. Exposure group: not applicable for this analysis.
26			(b) Indicate number of participants with missing data for each variable of interest
27			See the “Results” section, first period (page 7). Exposure group: not applicable for this analysis.
28			(c) Summarise follow-up time (eg, average and total amount)
29			“Results” section, second period (page 7). Exposure group: not applicable for this analysis..
30	Outcome data	15*	Report numbers of outcome events or summary measures over time
31			Number of events, by type, are reported in Table 1. Exposure group: not applicable for this analysis.
32	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included
33			The study model is reported in Table S1, supplementary material; the analysis is multivariable by nature.
34			(b) Report category boundaries when continuous variables were categorized
35			Not applicable
36			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
37			Not applicable
38	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
39			Not applicable
40			
41			
42			
43			
44			
45			
46			
47			
48			
49			
50			
51			
52			
53			
54			
55			
56			
57			
58			
59			
60			

Discussion			
Key results	18	Summarise key results with reference to study objectives	See the first part of the Discussion section, page 9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Study limitations are reported and discussed at pages 11-12.
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Done
Generalisability	21	Discuss the generalisability (external validity) of the study results	See pages 11-12
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Source of funding is reported at page 12.

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.



Long-term prediction of major coronary or ischemic stroke event in a low-incidence Southern European population: model development and evaluation of clinical utility

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003630.R1
Article Type:	Research
Date Submitted by the Author:	30-Sep-2013
Complete List of Authors:	Veronesi, Giovanni; Università degli Studi dell'Insubria, Dipartimento di Medicina Clinica e Sperimentale Gianfagna, Francesco; Università degli Studi dell'Insubria, Dipartimento di Medicina Clinica e Sperimentale Chambless, Lloyd; University of North Carolina at Chapel Hill, Biostatistics Giampaoli, Simona; Istituto Superiore di Sanità, Mancia, Guiseppe; Università di MILano-Bicocca, Dipartimento di medicina clinica e prevenzione Cesana, Giancarlo; Università di MILano-Bicocca, Dipartimento di medicina clinica e prevenzione Ferrario, Marco; Università degli Studi dell'Insubria, Dipartimento di Medicina Clinica e Sperimentale
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	Cardiac Epidemiology < CARDIOLOGY, Ischaemic heart disease < CARDIOLOGY, PREVENTIVE MEDICINE

SCHOLARONE™
Manuscripts

1
2
3
4 **Long-term prediction of major coronary or ischemic stroke event in a low-incidence**
5 **Southern European population: model development and evaluation of clinical utility**
6
7

8
9 **Short Title: Clinical utility of long-term CVD risk prediction in primary prevention**
10

11
12 Giovanni Veronesi¹, Francesco Gianfagna¹, Lloyd E Chambless², Simona Giampaoli³,
13 Giuseppe Mancia⁴, Giancarlo Cesana⁴, and Marco M Ferrario¹.
14

- 15
16
17 1. Research Centre in Epidemiology and Preventive Medicine, Department of Clinical and
18 Experimental Medicine. University of Insubria, Varese, Italy.
19 2. Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC,
20 USA
21 3. Istituto Superiore di Sanità, Roma, Italy
22 4. Department of Clinical Medicine, Prevention and Health Biotechnology, University of
23 Milano-Bicocca, Milano, Italy
24
25
26
27
28
29
30
31
32
33

34 Corresponding author:
35

36 Dr Giovanni Veronesi
37 Research Centre in Epidemiology and Preventive Medicine
38 University of Insubria
39 Via O Rossi, 9 - Padiglione Rossi, I piano
40 I-21100 Varese, Italy
41 Phone +39-0332-270696
42 Fax +39-0332-278986
43 giovanni.veronesi@uninsubria.it
44
45
46
47
48
49

50 **Key words:** long-term risk, prediction, cardiovascular disease, clinical utility, primary
51 prevention
52

53 **Word count: 2908**
54
55
56
57
58
59
60

ABSTRACT

Objective. To develop a long-term prediction model of first major cardiovascular event and to assess its clinical utility in a low-incidence European population.

Setting. Four independent population-based cohorts enrolled between 1986 and 1993 in Northern Italy.

Participants and methods. N=5,247 35-69 years old men and women free of cardiovascular disease at baseline. Absolute 20-year risk of first fatal or non-fatal coronary or ischemic stroke event (MONICA validated) was estimated from gender-specific Cox models.

Main outcome measures. Model discrimination (Area Under the ROC-Curve, AUC). “High-risk” subjects were defined based on several threshold values for the 20-year predicted risk. Clinical utility was defined in terms of fraction of missed events (events among those considered at low-risk) and unnecessary treatment (false:true positives ratio). A Net Benefit curve was also provided.

Results. Kaplan-Meier 20-year risk was 16.1% in men (315 events) and 6.1% in women (123 events). Model discrimination (AUC=0.737 in men, 0.801 in women) did not change significantly as compared to 10-year prediction time interval. In men, with respect to risk stratification based on the number of risk factors, a 20% predicted risk cut-off would miss less events (36% vs. 50%) and reduce unnecessary treatment (false:true positive ratio: 2.2 vs. 3.0); the Net Benefit was higher over the whole range of threshold values. Similar considerations hold for women.

Conclusions. Long-term prediction has good discrimination ability and is clinically useful for risk stratification in primary prevention. A clinical utility analysis is recommended to identify the optimal stratification according to different public health goals.

ARTICLE SUMMARY

Article focus

- Primary prevention of cardiovascular disease (CVD) has been recently moved towards the concepts of “lifetime” and “long-term” risk, especially in young subjects and women.
- There is no long-term risk prediction model available for low-incidence Southern European populations; in addition, the evaluation of the clinical benefit of long-term prediction has not been provided so far.
- We aim to develop a 20-year risk score equation in a northern Italian population of men and women considered at low incidence of major cardiovascular events; and to evaluate the clinical utility of the model for risk stratification in primary CVD prevention program.

Key Messages

- In our population, the 20-year risk model had satisfactory discrimination ability as compared to short-term risk prediction. The importance of long-term prediction for early identification of young subjects and women at increased likelihood of event during their remaining lifespan is confirmed.
- Risk stratification based on the predicted 20-year risk had a better clinical Net Benefit with respect to a stratification based on the number of risk factors, in men and women.
- In both genders, the optimal treatment allocation based on 20-year risk can be determined according to different public health strategies, i.e. either to reduce the fraction of events potentially un-prevented or to avoid un-necessary treatment.

Strengths and limitations of this study

- Our sample comprises subjects drawn from a representative northern Italian population, with a satisfactory participation rate. We also mention the high-quality of follow-up

1
2
3
4 procedures, including case ascertainment for non-fatal events and a consistent event
5
6 validation according to MONICA criteria over the whole follow-up period.
7

- 8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
- 28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Our 20-year risk prediction model is the first attempt to characterize long-term risk of first coronary or ischemic stroke event in a low-incidence European population. A limitation of our study is the lack of a formal external validation, although we provide a cross-validation analysis. We also remind that our underlying population is characterized by high levels of industrialization and urbanization, with one of the highest average incomes in Italy. Caution is therefore required before generalizing our findings to different contexts.

INTRODUCTION

Current European and American guidelines for primary prevention of major coronary and stroke events recommend the use of a multivariable risk prediction method to identify high risk subjects [1, 2]. Several risk scores are available in different US [3, 4] and European [5] populations of middle-aged adults, including the Italian one [6], to estimate the risk of first fatal and non-fatal cardiovascular event over a 10 year time interval. Primary prevention however has been recently moved towards the concepts of “lifetime” [7] and “long-term” risks [8], motivated also by the increasing life expectancy in western Countries. To this extent, 10-year risk prediction models are inadequate to distinguish between those at both low short-term and long-term risks, and those at low short-term but at elevated long-term risk due to the presence of non-optimal risk factors levels [9-11]. In the Framingham Study population, an unfavorable risk factor profile led to an increased 30-year risk of first cardiovascular event, independently on the age at the risk factors assessment [10]. In a

1
2
3
4 representative sample of the Italian population, about 80% of individuals classified at low 10-
5
6 year risk had increased lifetime risk according to US definition ($\geq 40\%$), potentially leading
7
8 to a consistent number of un-prevented events that might have been prevented if lifetime risk
9
10 had been considered [11]. This group was largely composed of women and young subjects,
11
12 suggesting that long-term prediction models for risk stratification may be even more
13
14 beneficial in populations at low incidence of cardiovascular disease [12]. To this extent, the
15
16 development of a specific long-term risk prediction should be preferred with respect to re-
17
18 calibration of risk models derived in high-incidence countries [13]. However, extending the
19
20 range of risk prediction is not a straightforward operation. Although several studies have
21
22 shown that a single measurement of risk factor is predictive of future events after 30 plus
23
24 years [10, 14], behavioral changes and risk factors modification may affect model
25
26 discrimination. High-quality follow-up data, with a consistent event definition and validation
27
28 over-time, are also required. Finally, subjects' stratification in risk categories is often based
29
30 on arbitrary cut-points of absolute risk [15] which may show no benefit in clinical practice
31
32 [16]. The evaluation of the clinical benefit of long-term prediction by means of some
33
34 standard measure [17] has not been provided so far and is therefore required [8].
35
36
37 The aim of the present paper is to develop a 20-year risk score equation in a European
38
39 population of men and women considered at low incidence of major cardiovascular events. In
40
41 addition to standard model calibration and discrimination tools, we evaluate the clinical
42
43 utility of the model for risk stratification.
44
45
46
47

48 **METHODS**

49 **Study population**

50
51 The Brianza population comprises residents in 173 municipalities in the area between Milan
52
53 and the Swiss border, Northern Italy. The CAMUNI study includes four independent
54
55
56
57
58
59
60

1
2
3
4 population surveys carried out between 1986 and 1994 as part of either the WHO-MONICA
5 Project [3 surveys; 18] or the PAMELA study [19]. Participation rates were 70.1%, 67.2%,
6 and 70.8% for the three MONICA surveys, respectively, and 64% for the PAMELA Study,
7 with no differences between men and women. Both the baseline screening and the follow-up
8 for all the surveys were approved by the ethical committee of the Monza Hospital.
9
10

11 **Baseline assessment of risk factors**

12
13 Cardiovascular risk factors were collected at baseline strictly adhering to the standardized
14 procedures and quality standards of the WHO-MONICA Project [20]. Height and weight
15 were measured on subjects without shoes and wearing light clothing. Trained technicians
16 collected blood pressure at right arm on subjects in sitting position and at rest, using a
17 standard mercury sphygmomanometer equipped with two side cuff bladders, for normal and
18 obese subjects. Systolic and diastolic blood pressure were assessed twice, at 5 minutes apart,
19 recording the first and fifth phase of the Korotkoff sounds. The study variable for systolic
20 blood pressure is the average of the two measurements. Venous blood specimens were taken
21 from the ante-cubital vein on fasting subjects (12 hours or more). Serum total cholesterol,
22 HDL-cholesterol and blood glucose were determined using the enzymatic methods; HDL-
23 cholesterol fraction was separated using the Phosphotungstate-Mg⁺⁺ method [20]. A
24 standardized interview was administered to participants by trained interviewers. Information
25 on the use of anti-hypertensive treatment in the last two weeks was dichotomised as yes/no;
26 similarly, cigarette smoking habit was dichotomised as current versus past/never smokers.
27
28 Diabetes mellitus was defined using self-reported diagnoses, information on insulin and oral
29 hypoglycaemic treatments and fasting blood glucose exceeding 7 mmol/L (126 mg/dl). The
30 presence at baseline of a previous history of MI, unstable angina pectoris, cardiac
31 revascularization or stroke was defined based on self-reported information.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Study endpoint and follow-up procedures

The study endpoint is defined as the occurrence of first major coronary event (myocardial infarction, acute coronary syndrome and coronary revascularization) as well as for first ischemic stroke or carotid endarterectomy, fatal and non-fatal [13]. Data completeness for fatal events was assured through a systematic collection of death certificates provided by local health units; vital status and death certificates were available for 99% of the subjects. Suspected out-of-hospital deaths were investigated through interview of relatives. Suspected hospitalized coronary (discharge code ICD-IX 410 or 411 and ICD-IX CM 36.0-9 for coronary revascularization) and stroke events (ICD-IX 430-432, 434, 436; ICD-IX CM 38.01-39.22 or 39.50-39.52 with at least one 430-438 as discharge code, for carotid endarterectomy) were identified through deterministic and probabilistic record linkages with regional hospital discharge databases, obtaining a satisfactory performance in case finding, as reported [18, 21]. All acute events were investigated and validated according to the MONICA diagnostic criteria [20]; the ischemic subtype for stroke was attributed after review of the available clinical information.

Statistical analysis

Our 20-year risk prediction model is based on gender-specific Cox regression models with age, total cholesterol, HDL-cholesterol, systolic blood pressure, anti-hypertensive treatment, cigarette smoking and diabetes. These predictors are core risk factors included in the CUORE Project [6, 13] as well as in other 10-year risk equations [3, 4]. After a preliminary check on linearity, total- and HDL-cholesterol were included in the model as categorical variables in four standard classes [4, 22]. The interaction between systolic blood pressure and anti-hypertensive treatment was not statistically significant (p-value 0.84 in men and 0.12 in women, respectively). There was no evidence of any cohort effect in the full model, in men

1
2
3
4 (3 df test p-value: 0.2) nor in women (p-value: 0.5). Finally, no violations in the proportional
5 hazard assumption were observed using a standard test for time-dependent variables.
6
7
8
9 Model calibration was assessed through the Grønnesby-Bogan goodness-of-fit test [23]. The
10 Area Under the ROC-curve (AUC), as well as sensitivity and specificity in the top and
11 bottom predicted risk quintiles, were computed taking censorship into account [24].
12
13 Correction for over-optimism and confidence intervals for the AUC were obtained through
14 1000 bootstrapped samples [25]. To assess the hypothesis of a loss in discrimination ability
15 due to a longer prediction period, we estimated the 10-year predicted probability of event in
16 our database, using the same set of risk factors but with shorter follow-up period, i.e. up to
17 the end of 2002 for all the subjects (number of events: 234 in men, 79 in women). We then
18 compared the AUC of the two models by looking at their respective bootstrapped confidence
19 intervals. To assess the clinical utility of the long-term model for risk stratification, we
20 considered two different public health goals. One is to decrease the number of events
21 occurring among those considered at “low-risk”. If we assume that a subject classified at
22 “high risk” will be targeted for prevention (either lifestyle intervention or treatment), any
23 event occurring outside this category is “not-identified” or “missed” by the prevention
24 strategy. The second strategy aims instead to reduce un-necessary treatment, by decreasing
25 the number of non-events among those considered at “high-risk”. Under the two scenarios,
26 “high-risk” subjects are defined as those with predicted risk above a certain cut-off value.
27 Clinical utility is defined in terms of *i*) fraction of “missed” events; *ii*) probability of event
28 among those classified at high risk; and *iii*) false positive/true positive ratio, for several
29 threshold values in the 20-year predicted risk. We also provide a decision curve analysis
30 based on the net benefit: $\text{Net Benefit} = (\text{true positives} - w \cdot \text{false positives})/n$, where n is the
31 sample size and the weight w represents the ratio between the harm of un-necessary treatment
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 and the harm of missing a case at that given value of predicted risk [17]. All the analyses
5
6 were conducted using the SAS software 9.2.
7

8 9 **RESULTS**

10
11 N=5,426 (2,703 men) subjects were enrolled in the age range 35-69 years. N=205 subjects
12
13 (3.8%; n=14 events) had at least one missing data; we considered data imputation (R
14
15 *transcan* function, [26]) and excluded only those with missing values in more than 4
16
17 covariates of interest (n=6 men and n=3 women). Finally n=120 men and n=45 women with a
18
19 positive history of CVD at baseline were also excluded, reducing the sample size to 2,574
20
21 men and 2,673 women.
22
23

24
25 Baseline characteristics of the study population, by gender, are shown in **Table 1**. During a
26
27 median follow-up time of 15 years (interquartile range: 12-20), we observed 315 first CVD
28
29 events in men (233 coronary events) and 123 in women (n=85 coronary events). The Kaplan-
30
31 Meier estimate for 20-year risk was 16.1% and 6.1% in men and women, respectively.
32

33 **Model development**

34
35 The beta-coefficients for the 20-year risk prediction model, as well as the baseline survival
36
37 term and the calibration slope [25], are provided in the Supplementary Material (**Table S1**).
38
39 All the risk factors were statistically significant, except for anti-hypertensive treatment,
40
41 though its point estimate reflected a 30% increase in hazard in both men and women; the
42
43 variable was retained in the model for comparability with the short-term CUORE model [6].
44
45 There were no significant differences in the set of beta estimates for the 20-year model as
46
47 compared to those from the 10-year risk model for the risk factors in the model (data not
48
49 shown). The model calibration was satisfactory, in men (Grønnesby-Bogan goodness-of-fit
50
51 chi-square 6.7, p-value 0.67) and in women (chi-square 9.6, p-value 0.38); calibration plots
52
53 are available as supplementary material (**Figure S1**)
54
55
56
57
58
59
60

1
2
3
4 We found no statistically significant difference in the overall discrimination ability between
5 long- and short-term prediction models, in men (0.736 vs. 0.731) and in women (0.801 vs.
6 0.816; **Table 2**). Only 5% of 20-year events in men occurred among subjects with a predicted
7 risk below the 20th percentile (bottom fifth); the corresponding figure in women is 2%. The
8 relative risk of event for being above the 80th percentile vs. below the 20th percentile of 20-
9 year risk was 9.5 (i.e. 35.1/3.7) in men and 22.4 (i.e. 20.2/0.9) in women. Finally, the value of
10 the 80th percentile for 20-year risk was more than twice as high than the similar percentile for
11 10-year risk in men (26.8 vs. 10.8) and more than three times as high in women (10.1 vs.
12 3.0). A similar consideration holds for the 20th percentile of risk or the median value.

23 **Clinical utility**

24
25 **Table 3a** and **Table 3b** describe strategies for the identification of high-risk subjects, based
26 on predicted 20-year risk, in men and women respectively. A cut-off value of 10% twenty
27 year risk in men would result in a 9% of “missed” events (i.e. events among those with
28 predicted risk below the cut-point), with a probability of event of 23% and one true positive
29 for every 3.4 false positive subjects (**Table 3a**). In the second scenario, by choosing the 20%
30 twenty year risk threshold value, the fraction of missed events was 36%. Note that about 30%
31 of events occurred for a predicted 20-year risk between 20% and 30%. Finally, using the
32 number of risk factors to define high risk subjects would result in a higher fraction of missed
33 events, with no changes in specificity or in the prevalence of subjects considered at high risk.
34 Among women, a cut-off value of 2% would result in a 5% of missed events, with a
35 probability of event of 9% and a true positive for every 10.1 false positive women (**Table**
36 **3b**). In the second scenario, the probability of event among those with absolute risk greater
37 than 10% was 20.4%, with a true positive for every 3.9 false positive subjects. However, the
38 fraction of missed events would be 32%; this number can be reduced by lowering the cut-off
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 value to 8%. By considering at high risk those with 2 or more risk factor would result in a
5
6 higher fraction of missed events, with no gain in specificity or in the probability of event in
7
8 the group. **Figure 1** illustrates the decision curve analysis based on the Net Benefit [17], for
9
10 men (left) and women (right). The figure suggests a greater net benefit for the predicted risk
11
12 with respect to the number of risk factors over the whole range of values, thus generalizing
13
14 the findings from Table 3a and Table 3b.
15
16

17 **DISCUSSION**

18
19 In this paper we present the 20-year prediction model of first major coronary or ischemic
20
21 stroke event in a Northern Italian population of men and women aged 35 to 69 years at
22
23 baseline. To our knowledge, this is the first long-term prediction model in a low-incidence,
24
25 European population. The discrimination ability of the long-term model did not significantly
26
27 drop with respect to a 10-year risk prediction model derived on the same population. Risk
28
29 stratification based on the predicted 20-year risk can be modulated according to different
30
31 prevention aims, i.e. either to reduce the fraction of events potentially un-prevented or to
32
33 avoid un-necessary treatment. Under both scenarios, the predicted 20-year risk showed an
34
35 overall better Net Benefit with respect to a risk stratification based on the number of risk
36
37 factors.
38
39

40
41 Our data confirmed previous findings on predictiveness of a single measurement of risk
42
43 factors on long-term CVD risk, in the Italian [27] as well as in other populations [10, 14].
44
45 Event discrimination for the 20-year risk prediction model did not change significantly from
46
47 10-year's, although in women it decreased from 0.814 to 0.801. In the Framingham Offspring
48
49 Study updating the baseline measurement of blood pressure and lipids with a later assessment
50
51 poorly affected model discrimination and reclassification [28] and cardiometabolic risk
52
53 factors clustering has been found to be quite stable over time [29].
54
55
56
57
58
59
60

1
2
3
4 As in the Framingham population, in our study the long-term predicted risk was more than
5 simply n -times the short-term risk prediction [10]. In addition in the age range 35 to 49
6
7
8 years, the long-term predicted risk in subjects with 1 or more non-optimal or elevated risk
9
10 factors (defined as in [7]) was 3-times the short-term risk in men, and 4-times in women (see
11
12 **Figure S2** in the Supplementary Material). This conveys the importance of long-term
13
14 prediction for early identification of young subjects and women at increased likelihood of
15
16 event during their remaining lifespan. We observed in our data a modest net reclassification
17
18 improvement (computed as in [24]) for the 20-year risk prediction model over the re-
19
20 calibrated 10-year risk, in men (1.8%) and in women (4.5%). The net reclassification
21
22 increased when we considered subjects with a low 10-year predicted risk but a cluster of 2 or
23
24 more risk factors (5.4% and 7.6% in men and women, respectively; data not shown).
25
26
27
28 Subjects' stratification is often based on arbitrarily-chosen thresholds of predicted risk [15],
29
30 which may limit the clinical utility of risk prediction models [16]. We considered two
31
32 strategies for the identification of "high-risk" subjects with contrasting goals, either to
33
34 decrease the fraction of missed events or to decrease unnecessary treatment. These can be
35
36 implemented by choosing threshold values for the predicted risk driven by either sensitivity
37
38 or by specificity, respectively. Despite the lowering costs of statin treatment with respect to
39
40 the costs of one un-prevented event, the high sensitivity scenario was not cost-effective over
41
42 a 10-year period [30]. These two scenarios might be combined to adopt a more complex risk
43
44 stratification, as often present in clinical practice [1-2, 12]. For instance, if we consider at
45
46 "low-risk" the 36% of men with 20-year absolute risk less than 10%, the fraction of missed
47
48 events would be 9%, i.e. 31 first events in 20 years. About 31% of men with absolute risk
49
50 between 10% and 20% could be addressed for lifestyle modification or treatment according
51
52 to the presence of specific risk factors; this category accounts for about 20% of cases. Finally,
53
54
55
56
57
58
59
60

1
2
3
4 the 33% of men with predicted risk above the 20% could be targeted with treatment
5
6 intervention; they account for 68% of events, and out of 3.2 treated men, one is a case. A
7
8 similar stratification can be provided for women, with different threshold values reflecting
9
10 gender-specific underlying risk as for the cardiovascular age assessment [15].
11
12

13 Among the study strengths and limitations, our sample comprises subjects drawn from a
14
15 representative northern Italian population, with a satisfactory participation rate. The
16
17 underlying population is characterized by high levels of industrialization and urbanization,
18
19 with one of the highest average incomes in Italy. A major limitation is the lack of an external
20
21 validation. External validation for long-term prediction models is in general an issue [10]; we
22
23 provide the over-optimism adjusted AUC as well as the calibration slope [25] to allow
24
25 applying our equation to different contexts (see Supplementary Material). We also mention a
26
27 high-quality of follow-up procedures, including case ascertainment for non-fatal events [21]
28
29 and a consistent event validation according to MONICA criteria, resulting in a Standardized
30
31 Incidence Rate for the study cohorts above 1 over the whole follow-up period [18]. Finally,
32
33 the study endpoint reflects the clinical need to treat the “global” ischemic risk of a given
34
35 patient, and not its separate components [3].
36
37
38

39 In conclusions, we provide a model to predict long-term risk of first major ischemic
40
41 cardiovascular event in a low-incidence population. Risk stratification based on long-term
42
43 risk can be clinically useful, especially for young subjects and women. A clinical utility
44
45 analysis is required to identify the optimal stratification, according to different public health
46
47 goals.
48
49
50
51
52
53
54
55
56
57
58
59
60

Funding

This work was supported by grants from the Health Administration of Regione Lombardia [grant number 10800/2009], as part of the Osservatorio Epidemiologico Cardiovascolare Regionale Lombardo.

Competing Interests

None.

Contributors

Conception and design: MMF, GM, GC and GV. All authors interpreted the data and critically reviewed the paper. Statistical analyses: GV, WC. GV drafted the manuscript and is the guarantor. All authors have read and approved the final version of the manuscript.

Data sharing

There is no additional data available.

REFERENCES

1. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). *Eur Heart J* 2012;33:1635-1701
2. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update : Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. *Circulation* 2002;106:388-391
3. D'Agostino RB, Ramachandran SV, Pencina MJ, et al. General cardiovascular risk profile for use in primary care. The Framingham Heart Study. *Circulation* 2008;117:743-753
4. Chambless LE, Folsom AR, Sharrett AR, et al. Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. *J Clin Epidemiol*. 2003;56:880-90
5. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal Cardiovascular disease in Europe: the SCORE project. *Eur Heart J* 2003;24:987-1003
6. Palmieri L, Panico S, Vanuzzo D, et al. Evaluation of the global cardiovascular absolute risk: the Progetto CUORE individual score. *Ann Ist Super Sanità* 2004;40:393-399.
7. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. *Circulation* 2006;113:791-798
8. Lloyd-Jones DM. Short-term versus long-term risk for coronary artery disease: implications for lipid guidelines. *Curr Opin Lipidol* 2006;17:619-625
9. Daviglius ML, Stamler J, Pirzada A, et al. Favourable cardiovascular risk profile in young women and long-term risk of cardiovascular and all-cause mortality. *JAMA* 2004;292:1588-1592
10. Pencina MJ, D'Agostino RB, Larson MG, et al. Predicting the 30-year risk of cardiovascular disease. The Framingham Heart Study. *Circulation* 2009;119:3078-3084
11. Di Castelnuovo A, Costanzo S, Persichillo M, et al. Distribution of short and lifetime risks for cardiovascular disease in Italians. *Eur J Prev Cardiol* 2011;19:723-730.
12. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: a guideline from the American Heart Association. *J Am Coll Cardiol* 2011;57:1404-1423

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
13. Ferrario MM, Chiodini P, Chambless LE, et al. Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation. *Int J Epidemiol* 2005;34:413-21
 14. Menotti A, Lanti M, Kafatos A, et al. The role of baseline casual blood pressure measurement and of blood pressure changes in middle age in prediction of cardiovascular and all-cause mortality occurring late in life: a cross-cultural comparison among the European cohorts of the Seven Countries Study. *J Hypertens* 2004;22:1683-1690
 15. Grover SA, Lowensteyn I. The challenges and benefits of cardiovascular risk assessment in clinical practice. *Can J Cardiol* 2011;27:481-487
 16. Collins GS, Altman DG. Predicting the 10 year risk of cardiovascular disease in the United Kingdom: independent and external validation of an updated version of QRISK2. *BMJ* 2012;344:e4181.
 17. Vickers AJ, Cronin AM, Elkin EB, et al. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. *Med Decis Making* 2008;8:53
 18. Ferrario M, Sega R, Chatenoud L, et al. Time trends of major coronary risk factors in a northern Italian population (1986-1994). How remarkable are socio-economic differences in an industrialised low CHD incidence country? *Int J Epidemiol* 2001;30:285-291.
 19. Cesana GC, De Vito G, Ferrario M, et al. Ambulatory blood pressure normalcy: The PAMELA Study. *J Hypertension Suppl* 1991;9:17-23.
 20. WWW-publications from the WHO MONICA Project. MONICA Manual. Available at: <http://www.thl.fi/publications/monica/manual/index.htm>.
 21. Fornari C, Madotto F, Demaria M, et al. Record-linkage procedures in epidemiology: an Italian multicentre study. *Epidemiol Prev* 2008;32:79-88.
 22. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factors category. *Circulation* 1998;97:1837-47
 23. May S., Hosmer DW. A simplified method of calculating an overall Goodness-of-Fit test for the Cox proportional hazards model. *Lifetime Data Anal* 1998;4:109-120
 24. Chambless LE, Cummiskey CP, and Cui G. Several methods to assess improvement in risk prediction models: extension to survival analysis. *Statist med* 2011;30:22-28
 25. Harrel FE, Lee KL and Marck DB. Tutorial in biostatistics: multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. *Statist med* 1996;15:361-387

1
2
3
4 26. Harrel FE. R reference manual: Package 'Hmisc'. Available at
5 <http://cran.r-project.org/web/packages/Hmisc/Hmisc.pdf>
6

7
8 27. Menotti A, Lanti M. Coronary risk factors predicting early and late coronary events.
9 *Heart* 2003;89:19-24
10

11 28. Bell K, Hayen A, McGeechan K, et al. Effects of additional blood pressure
12 and lipids measurements on the prediction of cardiovascular risk. *Eur J Prev Cardiol*
13 2012;19:1474-85
14

15 29. Camhi SM, Katzmarzyk PT. Tracking of cardiometabolic risk factor clustering from
16 childhood to adulthood. *Int J Pediatr Obes* 2010;5:122-129
17

18 30. Greving JP, Visseren FLJ, de Wit GA, Algra A. Statin treatment for primary prevention
19 of vascular disease: whom to treat? Cost-effectiveness analysis. *BMJ* 2011;342:d1672.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Tables and figures

Table 1. Baseline characteristics (mean (SD) or %) of the study population and number of incident events, by gender. Men and women, 35-69 years old, CVD-free at baseline.

	Men (n=2574)	Women (n=2673)
Age (years)	50.8 (9.1)	50.3 (9)
Years of schooling	8.5 (4.2)	7.3 (3.4)
Total Cholesterol (mmol/L)	5.8 (1.1)	5.8 (1.1)
HDL-Cholesterol (mmol/L)	1.3 (0.3)	1.6 (0.4)
Body Mass Index (Kg/m ²)	26.2 (3.5)	25.6 (4.7)
Systolic Blood Pressure (mmHg)	134.8 (19.3)	131.6 (20.2)
Diastolic Blood Pressure (mmHg)	85.9 (10.6)	82.8 (10.8)
Anti-hypertensive treatment (%)	11.8	16.0
Fasting plasma glucose (mmol/L)	5.4 (1.3)	5.1 (1.2)
Diabetes (%)	6.7	4.0
Current smoker (%)	37.1	19.6
Incident coronary event (n)	233	85
Incident ischemic strokes (n)	99	43
Incident CVD event (n)	315	123
20-year absolute risk of CVD [^]	16.1	6.1

[^]: Kaplan-Meier estimate.

Table 2. Discrimination ability for the 10-year and the 20-year risk prediction models. Men and women, 35-69 years old, CVD-free at baseline

	Men		Women	
	10-year risk	20-year risk	10-year risk	20-year risk
AUC (95% CI)	0.731 (0.702; 0.761)	0.737 (0.713; 0.764)	0.814 (0.779; 0.853)	0.801 (0.771; 0.833)
Subjects with predicted risk below the 20th percentile				
20th percentile of risk	2.3	6.3	0.3	1.1
Fraction of events* (%)	4.4	5.1	1.4	2.0
Probability of event in the group^ (%)	0.8	3.7	0.2	0.9
Subjects with predicted risk above the 80th percentile				
80th percentile of risk	10.8	26.8	3.0	10.1
Sensitivity* (%)	49.9	45.6	68.7	62.0
Specificity (%)	82.4	85.5	81.1	83.1
Probability of event in the group^ (%)	19.4	35.1	7.5	20.2

The Area Under the ROC-curve (AUC) was estimated taking censorship into account, and adjusting for over-optimism (n=1000 bootstrap).

*: Probability of belonging to the group, given that the subject is a case. ^: Kaplan-Meier estimate of the probability of event in the group.

Table 3a. Identification of high risk subjects based on the 20-year risk prediction model with respect to the number of risk factors, according to strategies aiming to *i*) reducing the fraction of missed events; and *ii*) reducing un-necessary treatment. Men, 35-69 years old, CVD-free at baseline

	Subjects at high risk		Fraction of missed events (%)	Specificity (%)	Probability of event* (%)	FP/TP Ratio
	n	%				
Strategy a: reduce the fraction of missed events						
All subjects	2574	100.0	0.0	-	16.1	5.2
1+ Major Risk Factor [#]	1842	71.6	13.7	32.5	19.5	4.1
20-year absolute risk > 10%	1645	63.9	9.1	41.2	22.9	3.4
20-year absolute risk > 15%	1169	45.4	22.1	60.9	27.7	2.6
Strategy b: reduce un-necessary treatment						
2+ Major Risk Factors [#]	828	32.2	50.4	73.6	24.9	3.0
20-year absolute risk > 20%	841	32.7	35.7	73.7	31.7	2.2
20-year absolute risk > 30%	415	16.1	62.6	88.9	37.4	1.7

“Missed” events are events occurring among subjects not classified at “high risk”, i.e. with 20-year absolute risk (or a number of risk factors) below the cut-off point.

*: Kaplan-Meier estimate of the probability of event in the group (positive predicted value).

FP = Number of False Positives; TP = Number of True Positives

[#]: total cholesterol > 240 mg/dl; HDL-cholesterol < 40 [men] or < 50 [women] mg/dl; systolic blood pressure > 160 mmHg; smoking; diabetes

Table 3b. Identification of high risk subjects based on the 20-year risk prediction model with respect to the number of risk factors, according to strategies aiming to *i*) reducing the fraction of missed events; and *ii*) reducing un-necessary treatment. Women, 35-69 years old, CVD-free at baseline

	Subjects at high risk		Fraction of missed events (%)	Specificity (%)	Probability of event* (%)	FP/TP Ratio
	n	%				
Strategy a: reduce the fraction of missed events						
All subjects	2673	100.0	0.0	-	6.1	15.3
1+ Major Risk Factor [#]	1654	61.9	17.7	40.1	8.2	11.3
20-year absolute risk > 2%	1733	64.8	4.5	37.4	9.0	10.1
20-year absolute risk > 5%	1067	39.9	14.7	63.2	13.1	6.6
Strategy b: reduce un-necessary treatment						
2+ Major Risk Factors [#]	640	23.9	42.3	79.5	14.8	5.8
20-year absolute risk > 8%	698	26.1	22.7	77.1	18.2	4.5
20-year absolute risk > 10%	545	20.4	32.1	82.7	20.4	3.9

“Missed” events are events occurring among subjects not classified at “high risk”, i.e. with 20-year absolute risk (or a number of risk factors) below the cut-off point.

*: Kaplan-Meier estimate of the probability of event in the group (positive predicted value).

FP = Number of False Positives; TP = Number of True Positives

#: total cholesterol > 240 mg/dl; HDL-cholesterol < 40 [men] or < 50 [women] mg/dl; systolic blood pressure > 160 mmHg; smoking; diabetes

1
2
3
4
5 **Figure 1:** Decision curve for the 20-year risk prediction model in the CAMUNI population, Northern Italy.
6 Men (left) and women (right), 35 to 69 years old, free of CVD at baseline.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

For peer review only

Net Benefit: $(TP - w * FP) / n$, where TP = True Positive; FP = False Positive; $w = (\text{Absolute risk threshold}) / (1 - (\text{Absolute risk threshold}))$; n=sample size
Number of risk factors: total cholesterol >240 mg/dl; HDL-cholesterol <40 [men] or <50 [women] mg/dl; systolic blood pressure >160 mmHg; smoking; diabetes

1
2
3
4
5
6
7
8 **Long-term prediction of major coronary or ischemic stroke event in a low-incidence**

9 **Southern European population: model development and evaluation of clinical utility**

Comment [g1]: Added. See reviewer 1, comment #1

10
11 **Short Title: Clinical utility of long-term CVD risk prediction in primary prevention**

12
13
14 Giovanni Veronesi¹, Francesco Gianfagna¹, Lloyd E Chambless², Simona Giampaoli³,
15 Giuseppe Mancia⁴, Giancarlo Cesana⁴, and Marco M Ferrario¹.

16
17
18 1. Research Centre in Epidemiology and Preventive Medicine, Department of Clinical and
19 Experimental Medicine. University of Insubria, Varese, Italy.

20 2. Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC,
21 USA

22 3. Istituto Superiore di Sanità, Roma, Italy

23 4. Department of Clinical Medicine, Prevention and Health Biotechnology, University of
24 Milano-Bicocca, Milano, Italy

25
26
27
28
29
30
31
32
33
34 Corresponding author:

35 Dr Giovanni Veronesi
36 Research Centre in Epidemiology and Preventive Medicine
37 University of Insubria
38 Via O Rossi, 9 - Padiglione Rossi, I piano
39 I-21100 Varese, Italy
40 Phone +39-0332-270696
41 Fax +39-0332-278986
42 giovanni.veronesi@uninsubria.it
43
44
45
46

47 **Key words:** long-term risk, prediction, cardiovascular disease, clinical utility, primary
48 prevention

49
50 **Word count: 2908**
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objective. To develop a long-term prediction model of first major cardiovascular event and to assess its clinical utility in a low-incidence European population.

Setting. Four independent population-based cohorts enrolled between 1986 and 1993 in Northern Italy.

Participants and methods. N=5,247 35-69 years old men and women free of cardiovascular disease at baseline. Absolute 20-year risk of first fatal or non-fatal coronary or ischemic stroke event (MONICA validated) was estimated from gender-specific Cox models.

Main outcome measures. Model discrimination (Area Under the ROC-Curve, AUC). “High-risk” subjects were defined based on several threshold values for the 20-year predicted risk. Clinical utility was defined in terms of fraction of missed events (events among those considered at low-risk) and unnecessary treatment (false:true positives ratio). A Net Benefit curve was also provided.

Results. Kaplan-Meier 20-year risk was 16.1% in men (315 events) and 6.1% in women (123 events). Model discrimination (AUC=0.737 in men, 0.801 in women) did not change significantly as compared to 10-year prediction time interval. In men, with respect to risk stratification based on the number of risk factors, a 20% predicted risk cut-off would miss less events (36% vs. 50%) and reduce unnecessary treatment (false:true positive ratio: 2.2 vs. 3.0); the Net Benefit was higher over the whole range of threshold values. Similar considerations hold for women.

Conclusions. Long-term prediction has good discrimination ability and is clinically useful for risk stratification in primary prevention. A clinical utility analysis is recommended to identify the optimal stratification according to different public health goals.

INTRODUCTION

Current European and American guidelines for primary prevention of major coronary and stroke events recommend the use of a multivariable risk prediction method to identify high risk subjects [1, 2]. Several risk scores are available in different US [3, 4] and European [5] populations of middle-aged adults, including the Italian one [6], to estimate the risk of first fatal and non-fatal cardiovascular event over a 10 year time interval. Primary prevention however has been recently moved towards the concepts of “lifetime” [7] and “long-term” risks [8], motivated also by the increasing life expectancy in western Countries. To this extent, 10-year risk prediction models are inadequate to distinguish between those at both low short-term and long-term risks, and those at low short-term but at elevated long-term risk due to the presence of non-optimal risk factors levels [9-11]. In the Framingham Study population, an unfavorable risk factor profile led to an increased 30-year risk of first cardiovascular event, independently on the age at the risk factors assessment [10]. In a representative sample of the Italian population, about 80% of individuals classified at low 10-year risk had increased lifetime risk according to US definition ($\geq 40\%$), potentially leading to a consistent number of un-prevented events that might have been prevented if lifetime risk had been considered [11]. This group was largely composed of women and young subjects, suggesting that long-term prediction models for risk stratification may be even more beneficial in populations at low incidence of cardiovascular disease [12]. To this extent, the development of a specific long-term risk prediction should be preferred with respect to re-calibration of risk models derived in high-incidence countries [13]. However, extending the range of risk prediction is not a straightforward operation. Although several studies have shown that a single measurement of risk factor is predictive of future events after 30 plus years [10, 14], behavioral changes and risk factors modification may affect model

1
2
3
4
5
6
7
8 discrimination. High-quality follow-up data, with a consistent event definition and validation
9 over-time, are also required. Finally, subjects' stratification in risk categories is often based
10 on arbitrary cut-points of absolute risk [15] which may show no benefit in clinical practice
11 [16]. The evaluation of the clinical benefit of long-term prediction by means of some
12 standard measure [17] has not been provided so far and is therefore required [8].
13
14

15
16
17 The aim of the present paper is to develop a 20-year risk score equation in a European
18 population of men and women considered at low incidence of major cardiovascular events. In
19 addition to standard model calibration and discrimination tools, we evaluate the clinical
20 utility of the model for risk stratification.
21
22
23
24

25 **METHODS**

26 **Study population**

27
28 The Brianza population comprises residents in 173 municipalities in the area between Milan
29 and the Swiss border, Northern Italy. The CAMUNI study includes four independent
30 population surveys carried out between 1986 and 1994 as part of either the WHO-MONICA
31 Project [3 surveys; 18] or the PAMELA study [19]. Participation rates were 70.1%, 67.2%,
32 and 70.8% for the three MONICA surveys, respectively, and 64% for the PAMELA Study,
33 with no differences between men and women. Both the baseline screening and the follow-up
34 for all the surveys were approved by the ethical committee of the Monza Hospital.
35
36
37
38
39
40
41

42 **Baseline assessment of risk factors**

43
44 Cardiovascular risk factors were collected at baseline strictly adhering to the standardized
45 procedures and quality standards of the WHO-MONICA Project [20]. Height and weight
46 were measured on subjects without shoes and wearing light clothing. Trained technicians
47 collected blood pressure at right arm on subjects in sitting position and at rest, using a
48 standard mercury sphygmomanometer equipped with two side cuff bladders, for normal and
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8 obese subjects. Systolic and diastolic blood pressure were assessed twice, at 5 minutes apart,
9 recording the first and fifth phase of the Korotkoff sounds. The study variable for systolic
10 blood pressure is the average of the two measurements. Venous blood specimens were taken
11 from the ante-cubital vein on fasting subjects (12 hours or more). Serum total cholesterol,
12 HDL-cholesterol and blood glucose were determined using the enzymatic methods; HDL-
13 cholesterol fraction was separated using the Phosphotungstate-Mg⁺⁺ method [20]. A
14 standardized interview was administered to participants by trained interviewers. Information
15 on the use of anti-hypertensive treatment in the last two weeks was dichotomised as yes/no;
16 similarly, cigarette smoking habit was dichotomised as current versus past/never smokers.
17 Diabetes mellitus was defined using self-reported diagnoses, information on insulin and oral
18 hypoglycaemic treatments and fasting blood glucose exceeding 7 mmol/L (126 mg/dl). The
19 presence at baseline of a previous history of MI, unstable angina pectoris, cardiac
20 revascularization or stroke was defined based on self-reported information.
21
22
23
24
25
26
27
28
29
30
31

32 **Study endpoint and follow-up procedures**

33
34 The study endpoint is defined as the occurrence of first major coronary event (myocardial
35 infarction, acute coronary syndrome and coronary revascularization) as well as for first
36 ischemic stroke or carotid endarterectomy, fatal and non-fatal [13]. Data completeness for
37 fatal events was assured through a systematic collection of death certificates provided by
38 local health units; vital status and death certificates were available for 99% of the subjects.
39 Suspected out-of-hospital deaths were investigated through interview of relatives. Suspected
40 hospitalized coronary (discharge code ICD-IX 410 or 411 and ICD-IX CM 36.0-9 for
41 coronary revascularization) and stroke events (ICD-IX 430-432, 434, 436; ICD-IX CM
42 38.01-39.22 or 39.50-39.52 with at least one 430-438 as discharge code, for carotid
43 endarterectomy) were identified through deterministic and probabilistic record linkages with
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8 regional hospital discharge databases, obtaining a satisfactory performance in case finding, as
9 reported [18, 21]. All acute events were investigated and validated according to the MONICA
10 diagnostic criteria [20]; the ischemic subtype for stroke was attributed after review of the
11 available clinical information.
12

13 14 15 **Statistical analysis**

16
17 The CUORE Project 10 year risk equation for the Italian population [6, 18] constituted the
18 base for the development of the 20 year risk prediction model. ~~Our 20-year risk prediction~~

Comment [g2]: Deleted; reviewer 2, comment #2

19
20 model is based on ~~We considered~~ gender-specific Cox regression models with age, total
21 cholesterol, HDL-cholesterol, systolic blood pressure, anti-hypertensive treatment, cigarette
22 smoking and diabetes. These predictors are core risk factors included in the CUORE Project

23
24
25 [6, 13] as well as in other 10-year risk equations [3, 4]. After a preliminary check on linearity,

Comment [g3]: Added; reviewer 2, comment #2

26
27
28 total- and HDL-cholesterol were included in the model as categorical variables in four
29 standard classes [4, 22]. The interaction between systolic blood pressure and anti-

30
31 hypertensive treatment was not statistically significant (p-value 0.84 in men and 0.12 in

32
33 women, respectively). There was no evidence of any cohort effect in the full model, in men

34
35 (3 df test p-value: 0.2) nor in women (p-value: 0.5). Finally, no violations in the proportional

Comment [g4]: Added; reviewer 1, comment #2

36
37 hazard assumption were observed using a standard test for time-dependent variables.

38
39 Model calibration was assessed through the Grønnesby-Bogan goodness-of-fit test [23]. The

40
41 Area Under the ROC-curve (AUC), as well as sensitivity and specificity in the top and

42
43 bottom predicted risk quintiles, were computed taking censorship into account [24].

44
45 Correction for over-optimism and confidence intervals for the AUC were obtained through

46
47 1000 bootstrapped samples [25]. To assess the hypothesis of a loss in discrimination ability

48
49 due to a longer prediction period, we estimated the 10-year predicted probability of event in

50
51 our database, using the same set of risk factors but with shorter follow-up period, i.e. up to

1
2
3
4
5
6
7
8 the end of 2002 for all the subjects (number of events: 234 in men, 79 in women). We then
9
10 compared the AUC of both models, by considering bootstrapped confidence intervals for the
11
12 difference in the betas. We then compared the AUC of the two models by looking at their
13
14 respective bootstrapped confidence intervals.

Comment [G5]: Added; reviewer 1, comment #10

Comment [G6]: Rewording of this sentence below; reviewer 1, comment #9

15
16 To assess the clinical utility of the long-term model for risk stratification, we considered two
17
18 different public health goals. One is to decrease the number of events occurring among those
19
20 considered at “low-risk”. If we assume that a subject classified at “high risk” will be targeted
21
22 for prevention (either lifestyle intervention or treatment), any event occurring outside this
23
24 category is “not-identified” or “missed” by the prevention strategy. The second strategy aims
25
26 instead to reduce un-necessary treatment, by decreasing the number of non-events among
27
28 those considered at “high-risk”. Under the two scenarios, “high-risk” subjects are defined as
29
30 those with predicted risk above a certain cut-off value. Clinical utility is defined in terms of
31
32 *i)* fraction of “missed” events; *ii)* probability of event among those classified at high risk; and
33
34 *iii)* false positive/true positive ratio, for several threshold values in the 20-year predicted risk.
35
36 We also provide a decision curve analysis based on the net benefit: Net Benefit = (true
37
38 positives - w*false positives)/n, where n is the sample size and the weight w represents the
39
40 ratio between the harm of un-necessary treatment and the harm of missing a case at that given
41
42 value of predicted risk [17]. All the analyses were conducted using the SAS software 9.2.

43 RESULTS

44 N=5,426 (2,703 men) subjects were enrolled in the age range 35-69 years. N=205 subjects
45
46 (3.8%; n=14 events) had at least one missing data; we considered data imputation (R
47
48 *transcan* function, [26]) and excluded only those with missing values in more than 4
49
50 covariates of interest (n=6 men and n=3 women). Finally n=120 men and n=45 women with a
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8 positive history of CVD at baseline were also excluded, reducing the sample size to 2,574
9 men and 2,673 women.

10
11 Baseline characteristics of the study population, by gender, are shown in **Table 1**. During a
12 median follow-up time of 15 years (interquartile range: 12-20), we observed 315 first CVD
13 events in men (233 coronary events) and 123 in women (n=85 coronary events). The Kaplan-
14 Meier estimate for 20-year risk was 16.1% and 6.1% in men and women, respectively.
15
16
17
18

19 **Model development**

20
21 The beta-coefficients for the 20-year risk prediction model, as well as the baseline survival
22 term and the calibration slope [25], are provided in the Supplementary Material (**Table S1**).
23

24 All the risk factors were statistically significant, except for anti-hypertensive treatment,
25 though its point estimate reflected a 30% increase in hazard in both men and women; the
26 variable was retained in the model for comparability with the short-term CUORE model [6].
27
28
29

30 There were no significant differences in the set of beta estimates for the 20-year model as
31 compared to those from the 10-year risk model for the risk factors in the model (data not
32 shown). The model calibration was satisfactory, in men (Grønnesby-Bogan goodness-of-fit
33 chi-square 6.7, p-value 0.67) and in women (chi-square 9.6, p-value 0.38); [calibration plots](#)
34
35
36

37
38
39 [are available as supplementary material \(Figure S1\)](#);

Comment [G7]: Added; reviewer 1, comment #8

40
41 We found no statistically significant difference in the overall discrimination ability between
42 long- and short-term prediction models, in men (0.736 vs. 0.731) and in women (0.801 vs.
43 0.816; **Table 2**). Only 5% of 20-year events in men occurred among subjects with a predicted
44 risk below the 20th percentile (bottom [quintile fifth](#)); the corresponding figure in women is
45 2%. The relative risk of event for being above the 80th percentile vs. below the 20th percentile
46 of 20-year risk was 9.5 (i.e. 35.1/3.7) in men and 22.4 (i.e. 20.2/0.9) in women. Finally, the
47 value of the 80th percentile for 20-year risk was more than twice as high than the similar
48
49
50
51
52
53
54
55
56
57
58
59
60

Comment [g8]: Reviewer 1, comment #7

1
2
3
4
5
6
7
8 percentile for 10-year risk in men (26.8 vs. 10.8) and more than three times as high in women
9
10 (10.1 vs. 3.0). A similar consideration holds for the 20th percentile of risk or the median
11
12 value.

13 **Clinical utility**

14
15 **Table 3a** and **Table 3b** describe strategies for the identification of high-risk subjects, based
16
17 on predicted 20-year risk, in men and women respectively. A cut-off value of 10% twenty
18
19 year risk in men would result in a 9% of “missed” events (i.e. events among those with
20
21 predicted risk below the cut-point), with a probability of event of 23% and one true positive
22
23 for every 3.4 false positive subjects (**Table 3a**). In the second scenario, by choosing the 20%
24
25 twenty year risk threshold value, the fraction of missed events was 36%. Note that about 30%
26
27 of events occurred for a predicted 20-year risk between 20% and 30%. Finally, using the
28
29 number of risk factors to define high risk subjects would result in a higher fraction of missed
30
31 events, with no changes in specificity or in the prevalence of subjects considered at high risk.
32
33 Among women, a cut-off value of 2% would result in a 5% of missed events, with a
34
35 probability of event of 9% and a true positive for every 10.1 false positive women (**Table**
36
37 **3b**). In the second scenario, the probability of event among those with absolute risk greater
38
39 than 10% was 20.4%, with a true positive for every 3.9 false positive subjects. However, the
40
41 fraction of missed events would be 32%; this number can be reduced by lowering the cut-off
42
43 value to 8%. By considering at high risk those with 2 or more risk factor would result in a
44
45 higher fraction of missed events, with no gain in specificity or in the probability of event in
46
47 the group. **Figure 1** illustrates the decision curve analysis based on the Net Benefit [17], for
48
49 men (left) and women (right). The figure suggests a greater net benefit for the predicted risk
50
51 with respect to the number of risk factors over the whole range of values, thus generalizing
52
53 the findings from Table 3a and Table 3b.
54
55
56
57
58
59
60

DISCUSSION

In this paper we present the 20-year prediction model of first major coronary or ischemic stroke event in a Northern Italian population of men and women aged 35 to 69 years at baseline. To our knowledge, this is the first long-term prediction model in a low-incidence, European population. The discrimination ability of the long-term model did not significantly drop with respect to a 10-year risk prediction model derived on the same population. Risk stratification based on the predicted 20-year risk can be modulated according to different prevention aims, i.e. either to reduce the fraction of events potentially un-prevented or to avoid un-necessary treatment. Under both scenarios, the predicted 20-year risk showed an overall better Net Benefit with respect to a risk stratification based on the number of risk factors.

Our data confirmed previous findings on predictiveness of a single measurement of risk factors on long-term CVD risk, in the Italian [27] as well as in other populations [10, 14]. Event discrimination for the 20-year risk prediction model did not change significantly from 10-year's, although in women it decreased from 0.814 to 0.801. In the Framingham Offspring Study updating the baseline measurement of blood pressure and lipids with a later assessment poorly affected model discrimination and reclassification [28] and cardiometabolic risk factors clustering has been found to be quite stable over time [29].

As in the Framingham population, in our study the long-term predicted risk was more than simply n -times the short-term risk prediction [10]. In addition in the age range 35 to 49 years, the long-term predicted risk in subjects with 1 or more non-optimal or elevated risk factors (defined as in [7]) was 3-times the short-term risk in men, and 4-times in women (see

Figure S12 in the Supplementary Material). This conveys the importance of long-term prediction for early identification of young subjects and women at increased likelihood of

Comment [g9]: Calibration plot has been added as Figure S1, and this becomes Figure S2

1
2
3
4
5
6
7
8 event during their remaining lifespan. We observed in our data a modest net reclassification
9
10 improvement (computed as in [24]) for the 20-year risk prediction model over the re-
11
12 calibrated 10-year risk, in men (1.8%) and in women (4.5%). The net reclassification
13
14 increased when we considered subjects with a low 10-year predicted risk but a cluster of 2 or
15
16 more risk factors (5.4% and 7.6% in men and women, respectively; data not shown).
17
18 Subjects' stratification is often based on arbitrarily-chosen thresholds of predicted risk [15],
19
20 which may limit the clinical utility of risk prediction models [16]. We considered two
21
22 strategies for the identification of "high-risk" subjects with contrasting goals, either to
23
24 decrease the fraction of missed events or to decrease un-necessary treatment. These can be
25
26 implemented by choosing threshold values for the predicted risk driven by either sensitivity
27
28 or by specificity, respectively. Despite the lowering costs of statin treatment with respect to
29
30 the costs of one un-prevented event, the high sensitivity scenario was not cost-effective over
31
32 a 10-year period [30]. might not be cost-effective [30]. These two scenarios might be
33
34 combined to adopt a more complex risk stratification, as often present in clinical practice [1-
35
36 2, 12]. For instance, if we consider at "low-risk" the 36% of men with 20-year absolute risk
37
38 less than 10%, the fraction of missed events would be 9%, i.e. 31 first events in 20 years.
39
40 About 31% of men with absolute risk between 10% and 20% could be addressed for lifestyle
41
42 modification or treatment according to the presence of specific risk factors; this category
43
44 accounts for about 20% of cases. Finally, the 33% of men with predicted risk above the 20%
45
46 could be targeted with treatment intervention; they account for 68% of events, and out of 3.2
47
48 treated men, one is a case. A similar stratification can be provided for women, with different
49
50 threshold values reflecting gender-specific underlying risk as for the cardiovascular age
51
52 assessment [15].
53
54
55
56
57
58
59
60

Comment [G10]: Modified. See reviewer 2, comment #3

1
2
3
4
5
6
7
8 Among the study strengths and limitations, our sample comprises subjects drawn from a
9 representative northern Italian population, with a satisfactory participation rate. The
10 underlying population is characterized by high levels of industrialization and urbanization,
11 with one of the highest average incomes in Italy. A major limitation is the lack of an external
12 validation. External validation for long-term prediction models is in general an issue [10]; we
13 provide the over-optimism adjusted AUC as well as the , although we provide As
14 Supplementary Material we provide the baseline survival term as well as a calibration slope
15 [25] to allow applying our equation to different contexts (see Supplementary Material).
16 However, a validation study in a different population might be desirable to investigate the
17 generalizability of our findings. We also mention a high-quality of follow-up procedures,
18 including case ascertainment for non-fatal events [21] and a consistent event validation
19 according to MONICA criteria, resulting in a Standardized Incidence Rate for the study
20 cohorts above 1 over the whole follow-up period [18]. Finally, the study endpoint reflects the
21 clinical need to treat the “global” ischemic risk of a given patient, and not its separate
22 components [3].

23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

In conclusions, we provide a model to predict long-term risk of first major ischemic cardiovascular event in a low-incidence population. Risk stratification based on long-term risk can be clinically useful, especially for young subjects and women. A clinical utility analysis is required to identify the optimal stratification, according to different public health goals.

Funding

Comment [G11]: Modified; see reviewer 2, comment #5

Comment [G12]: Deleted; see reviewer #2, comment #5

1
2
3
4
5
6
7
8 This work was supported by grants from the Health Administration of Regione Lombardia
9 [grant number 10800/2009], as part of the Osservatorio Epidemiologico Cardiovascolare
10 Regionale Lombardo.
11

12 **Competing Interests**

13
14
15 None.

16 **Contributors**

17
18 Conception and design: MMF, GM, GC and GV. All authors interpreted the data and
19 critically reviewed the paper. Statistical analyses: GV, WC. GV drafted the manuscript and is
20 the guarantor. All authors have read and approved the final version of the manuscript.
21
22
23

24 **Data sharing**

25
26 There is no additional data available
27

28 **ARTICLE SUMMARY**

29 **Article focus**

- 30
31
32
- 33 ▪ Primary prevention of cardiovascular disease (CVD) has been recently moved towards
34 the concepts of “lifetime” and “long-term” risk, especially in young subjects and women.
 - 35
36 ▪ There is no long-term risk prediction model available for low-incidence Southern
37 European populations; in addition, the evaluation of the clinical benefit of long-term
38 prediction has not been provided so far.
 - 39
40 ▪ We aim to develop a 20-year risk score equation in a northern Italian population of men
41 and women considered at low incidence of major cardiovascular events; and to evaluate
42 the clinical utility of the model for risk stratification in primary CVD prevention program.
43
44
45
46
47

48 **Key Messages**

- 49
50 ▪ In our population, the 20-year risk model had satisfactory discrimination ability as
51 compared to short-term risk prediction. The importance of long-term prediction for early
52
53
54
55

1
2
3
4
5
6
7
8 identification of young subjects and women at increased likelihood of event during their
9 remaining lifespan is confirmed.

- 11 ■ Risk stratification based on the predicted 20-year risk had a better clinical Net Benefit
12 with respect to a stratification based on the number of risk factors, in men and women.
- 13
14 ■ In both genders, the optimal treatment allocation based on 20-year risk can be determined
15 according to different public health strategies, i.e. either to reduce the fraction of events
16 potentially un-prevented or to avoid un-necessary treatment.
17
18
19

20 21 **Strengths and limitations of this study**

- 22 ■ Our sample comprises subjects drawn from a representative northern Italian population,
23 with a satisfactory participation rate. We also mention the high-quality of follow-up
24 procedures, including case ascertainment for non-fatal events and a consistent event
25 validation according to MONICA criteria over the whole follow-up period.
26
27
28
29
30
31 ■ Our 20-year risk prediction model is the first attempt to characterize long-term risk of
32 first coronary or ischemic stroke event in a low-incidence European population. [A](#)
33 [limitation of our study is the lack of a formal external validation, although we provide a](#)
34 [cross-validation analysis. ~~To allow applying our equation to different populations, as~~](#)
35 [Supplementary Material we provide the baseline survival term as well as the calibration](#)
36 [slope. ~~However, an external validation study might be desirable.~~](#) We also remind that our
37 underlying population is characterized by high levels of industrialization and
38 urbanization, with one of the highest average incomes in Italy. Caution is therefore
39 required before generalizing our findings to different contexts.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Comment [G13]: Added; see reviewer 2, comment #5

Comment [G14]: Deleted; see reviewer 2, comment #5

REFERENCES

1. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). *Eur Heart J* 2012;33:1635-1701
2. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update : Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. *Circulation* 2002;106:388-391
3. D'Agostino RB, Ramachandran SV, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care. The Framingham Heart Study. *Circulation* 2008;117:743-753
4. Chambless LE, Folsom AR, Sharrett AR, Sorlie P, Couper D, Szklo M, Nieto FJ. Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. *J Clin Epidemiol.* 2003;56:880-90
5. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal Cardiovascular disease in Europe: the SCORE project. *Eur Heart J* 2003;24:987-1003
6. Palmieri L, Panico S, Vanuzzo D, Ferrario M, Pilotto L, Sega R, Cesana G, Giampaoli S per il gruppo di ricerca del Progetto CUORE. Evaluation of the global cardiovascular absolute risk: the Progetto CUORE individual score. *Ann Ist Super Sanità* 2004;40:393-399.
7. Lloyd-Jones DM, Leip EP, Larson MG, D'Agostino RB, Beiser A, Wilson PWF, Wolf P, Levy D. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. *Circulation* 2006;113:791-798
8. Lloyd-Jones DM. Short-term versus long-term risk for coronary artery disease: implications for lipid guidelines. *Curr Opin Lipidol* 2006;17:619-625
9. Daviglius ML, Stamler J, Pirzada A, Yan LL, Garside DB, Liu K, Wang R, Dyer AR, Lloyd-Jones DM, Greenland P. Favourable cardiovascular risk profile in young women and long-term risk of cardiovascular and all-cause mortality. *JAMA* 2004;292:1588-1592
10. Pencina MJ, D'Agostino RB, Larson MG, Massaro JM, Vasan RS. Predicting the 30-year risk of cardiovascular disease. The Framingham Heart Study. *Circulation* 2009;119:3078-3084
11. Di Castelnuovo A, Costanzo S, Persichillo M, Olivieri M, de Curtis A, Zito F, Donati MB, de Gaetano G, Iacoviello L. Distribution of short and lifetime risks for cardiovascular disease in Italians. *Eur J Prev Cardiol* 2011;19:723-730.

- 1
2
3
4
5
6
7
8
9 12. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, et al. Effectiveness-
10 based guidelines for the prevention of cardiovascular disease in women—2011 update: a
11 guideline from the American Heart Association. *J Am Coll Cardiol* 2011;57:1404–1423
12
13 13. Ferrario MM, Chiodini P, Chambless LE, Cesana G, Vanuzzo D, Panico S, Sega R,
14 Pilotto L, Palmieri L and Giampaoli S for the CUORE Project Research Group. Prediction of
15 coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort
16 Study prediction equation. *Int J Epidemiol* 2005;34:413-21
17
18 14. Menotti A, Lanti M, Kafatos A, Nissinen A, Dontas A, Nedeljkovic S, Kromhout D, for
19 the Seven Countries Study. The role of baseline casual blood pressure measurement and of
20 blood pressure changes in middle age in prediction of cardiovascular and all-cause mortality
21 occurring late in life: a cross-cultural comparison among the European cohorts of the Seven
22 Countries Study. *J Hypertens* 2004;22:1683-1690
23
24 15. Grover SA, Lowensteyn I. The challenges and benefits of cardiovascular risk assessment
25 in clinical practice. *Can J Cardiol* 2011;27:481-487
26
27 16. Collins GS, Altman DG. Predicting the 10 year risk of cardiovascular disease in the
28 United Kingdom: independent and external validation of an updated version of QRISK2.
29 *BMJ* 2012;344:e4181.
30
31 17. Vickers AJ, Cronin AM, Elkin EB, Gonen M. Extensions to decision curve analysis, a
32 novel method for evaluating diagnostic tests, prediction models and molecular markers. *Med
33 Decis Making* 2008;8:53
34
35 18. Ferrario M, Sega R, Chatenoud L, et al. Time trends of major coronary risk factors in a
36 northern Italian population (1986-1994). How remarkable are socio-economic differences in
37 an industrialised low CHD incidence country? *Int J Epidemiol* 2001;30:285-291.
38
39 19. Cesana GC, De Vito G, Ferrario M, et al. Ambulatory blood pressure normalcy: The
40 PAMELA Study. *J Hypertension Suppl* 1991;9:17-23.
41
42 20. WWW-publications from the WHO MONICA Project. MONICA Manual. Available at:
43 <http://www.thl.fi/publications/monica/manual/index.htm>.
44
45 21. Fornari C, Madotto F, Demaria M, Romanelli A, Pepe P, Raciti M, Tancioni V, Chini F,
46 Trerotoli P, Bartolomeo N, Serio G, Cesana G, Corrao G. Record-linkage procedures in
47 epidemiology: an Italian multicentre study. *Epidemiol Prev* 2008;32:79-88.
48
49 22. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannell WB.
50 Prediction of coronary heart disease using risk factors category. *Circulation* 1998;97:1837-47
51
52 23. May S., Hosmer DW. A simplified method of calculating an overall Goodness-of-Fit test
53 for the Cox proportional hazards model. *Lifetime Data Anal* 1998;4:109-120
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9 24. Chambless LE, Cummiskey CP, and Cui G. Several methods to assess improvement in
10 risk prediction models: extension to survival analysis. *Statist med* 2011;30:22–28
11
12 25. Harrel FE, Lee KL and Marck DB. Tutorial in biostatistics: multivariable prognostic
13 models: issues in developing models, evaluating assumptions and adequacy, and measuring
14 and reducing errors. *Statist med* 1996;15:361–387
15
16 26. Harrel FE. R reference manual: Package ‘Hmisc’. Available at
17 <http://cran.r-project.org/web/packages/Hmisc/Hmisc.pdf>
18
19 27. Menotti A, Lanti M. Coronary risk factors predicting early and late coronary events.
20 *Heart* 2003;89:19-24
21
22 28. Bell K, Hayen A, McGeechan K, Neal B, Irwig L. Effects of additional blood pressure
23 and lipids measurements on the prediction of cardiovascular risk. *Eur J Prev Cardiol*
24 2012;19:1474-85
25
26 29. Camhi SM, Katzmarzyk PT. Tracking of cardiometabolic risk factor clustering from
27 childhood to adulthood. *Int J Pediatr Obes* 2010;5:122-129
28
29 30. Greving JP, Visseren FLJ, de Wit GA, Algra A. Statin treatment for primary prevention
30 of vascular disease: whom to treat? Cost-effectiveness analysis. *BMJ* 2011;342:d1672.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8 **Tables and figures**

9 **Table 1.** Baseline characteristics (mean (SD) or %) of the study population and number of incident events, by gender.
10 Men and women, 35-69 years old, CVD-free at baseline.

	Men (n=2574)	Women (n=2673)
Age (years)	50.8 (9.1)	50.3 (9)
Years of schooling	8.5 (4.2)	7.3 (3.4)
Total Cholesterol (mmol/L)	5.8 (1.1)	5.8 (1.1)
HDL-Cholesterol (mmol/L)	1.3 (0.3)	1.6 (0.4)
Body Mass Index (Kg/m ²)	26.2 (3.5)	25.6 (4.7)
Systolic Blood Pressure (mmHg)	134.8 (19.3)	131.6 (20.2)
Diastolic Blood Pressure (mmHg)	85.9 (10.6)	82.8 (10.8)
Anti-hypertensive treatment (%)	11.8	16.0
Fasting plasma glucose (mmol/L)	5.4 (1.3)	5.1 (1.2)
Diabetes (%)	6.7	4.0
Current smoker (%)	37.1	19.6
Incident coronary event (n)	233	85
Incident ischemic strokes (n)	99	43
Incident CVD event (n)	315	123
20-year absolute risk of CVD [^]	16.1	6.1

36 [^]: Kaplan-Meier estimate.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 2. Discrimination ability for the 10-year and the 20-year risk prediction models. Men and women, 35-69 years old, CVD-free at baseline

	Men		Women	
	10-year risk	20-year risk	10-year risk	20-year risk
AUC (95% CI)	0.731 (0.702; 0.761)	0.737 (0.713; 0.764)	0.814 (0.779; 0.853)	0.801 (0.771; 0.833)
Subjects with predicted risk below the 20th percentile				
20th percentile of risk	2.3	6.3	0.3	1.1
Fraction of events* (%)	4.4	5.1	1.4	2.0
Probability of event in the group^ (%)	0.8	3.7	0.2	0.9
Subjects with predicted risk above the 80th percentile				
80th percentile of risk	10.8	26.8	3.0	10.1
Sensitivity* (%)	49.9	45.6	68.7	62.0
Specificity (%)	82.4	85.5	81.1	83.1
Probability of event in the group^ (%)	19.4	35.1	7.5	20.2

The Area Under the ROC-curve (AUC) was estimated taking censorship into account, and adjusting for over-optimism (n=1000 bootstrap).
*: Probability of belonging to the group, given that the subject is a case. ^: Kaplan-Meier estimate of the probability of event in the group.

Table 3a. Identification of high risk subjects based on the 20-year risk prediction model with respect to the number of risk factors, according to strategies aiming to *i)* reducing the fraction of missed events; and *ii)* reducing un-necessary treatment. Men, 35-69 years old, CVD-free at baseline

	Subjects at high risk		Fraction of missed events (%)	Specificity (%)	Probability of event* (%)	FP/TP Ratio
	n	%				
Strategy a: reduce the fraction of missed events						
All subjects	2574	100.0	0.0	-	16.1	5.2
1+ Major Risk Factor [#]	1842	71.6	13.7	32.5	19.5	4.1
20-year absolute risk > 10%	1645	63.9	9.1	41.2	22.9	3.4
20-year absolute risk > 15%	1169	45.4	22.1	60.9	27.7	2.6
Strategy b: reduce un-necessary treatment						
2+ Major Risk Factors [#]	828	32.2	50.4	73.6	24.9	3.0
20-year absolute risk > 20%	841	32.7	35.7	73.7	31.7	2.2
20-year absolute risk > 30%	415	16.1	62.6	88.9	37.4	1.7

“Missed” events are events occurring among subjects not classified at “high risk”, i.e. with 20-year absolute risk (or a number of risk factors) below the cut-off point.

*: Kaplan-Meier estimate of the probability of event in the group (positive predicted value).

FP = Number of False Positives; TP = Number of True Positives

[#]: total cholesterol > 240 mg/dl; HDL-cholesterol < 40 [men] or < 50 [women] mg/dl; systolic blood pressure > 160 mmHg; smoking; diabetes

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 3b. Identification of high risk subjects based on the 20-year risk prediction model with respect to the number of risk factors, according to strategies aiming to *i)* reducing the fraction of missed events; and *ii)* reducing un-necessary treatment. Women, 35-69 years old, CVD-free at baseline

	Subjects at high risk		Fraction of missed events (%)	Specificity (%)	Probability of event* (%)	FP/TP Ratio
	n	%				
Strategy a: reduce the fraction of missed events						
All subjects	2673	100.0	0.0	-	6.1	15.3
1+ Major Risk Factor [#]	1654	61.9	17.7	40.1	8.2	11.3
20-year absolute risk > 2%	1733	64.8	4.5	37.4	9.0	10.1
20-year absolute risk > 5%	1067	39.9	14.7	63.2	13.1	6.6
Strategy b: reduce un-necessary treatment						
2+ Major Risk Factors [#]	640	23.9	42.3	79.5	14.8	5.8
20-year absolute risk > 8%	698	26.1	22.7	77.1	18.2	4.5
20-year absolute risk > 10%	545	20.4	32.1	82.7	20.4	3.9

“Missed” events are events occurring among subjects not classified at “high risk”, i.e. with 20-year absolute risk (or a number of risk factors) below the cut-off point.

*: Kaplan-Meier estimate of the probability of event in the group (positive predicted value).

FP = Number of False Positives; TP = Number of True Positives

[#]: total cholesterol > 240 mg/dl; HDL-cholesterol < 40 [men] or < 50 [women] mg/dl; systolic blood pressure > 160 mmHg; smoking; diabetes

1
2
3
4
5
6
7
8 **Figure 1:** Decision curve for the 20-year risk prediction model in the CAMUNI population, Northern Italy.
9 Men (left) and women (right), 35 to 69 years old, free of CVD at baseline.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 Net Benefit: $(TP - w * FP) / n$, where TP = True Positive; FP = False Positive; $w = (\text{Absolute risk threshold}) / (1 - (\text{Absolute risk threshold}))$; n=sample size
38 Number of risk factors: total cholesterol >240 mg/dl; HDL-cholesterol <40 [men] or <50 [women] mg/dl; systolic blood pressure >160 mmHg; smoking; diabetes
39
40
41
42
43
44
45

22

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Supplementary material

For peer review only

Table S1: Beta-coefficients, standard errors and baseline survival for the 20-year risk prediction model in Northern Italy. Men and women, 35 to 69 years old, free of CVD at baseline.

	Men			Women		
	Beta	SE	p-value	Beta	SE	p-value
Age (years)	0.058	0.008	<.0001	0.084	0.014	<.0001
Total Cholesterol[^]						
200-240 mg/dl	0.388	0.161		0.553	0.287	
240-280 mg/dl	0.690	0.167	<.0001	0.607	0.310	0.027
> 280 mg/dl	0.923	0.198		0.996	0.328	
HDL-Cholesterol[°]						
<45 mg/dl	0.403	0.160		0.804	0.250	
45-50 mg/dl	0.367	0.186	0.013	0.364	0.309	0.015
50-60 mg/dl	0.024	0.177		0.261	0.225	
Systolic Blood Pressure (mmHg)	0.011	0.003	0.0003	0.015	0.005	0.001
Anti-hypertensive treatment (yes/no)	0.247	0.154	0.11	0.267	0.209	0.20
Smoking (yes/no)	0.521	0.117	<.0001	0.994	0.216	<.0001
Diabetes (yes/no)	0.744	0.163	<.0001	1.020	0.249	<.0001
Baseline 20-year survival ($S_0(20)$)*		0.94168			0.98502	
G(μ)		4.35638			6.20915	
Calibration Slope		0.948			0.937	

SE = Standard Error. [^]: reference group: total cholesterol \leq 200 mg/dl. [°]: reference group: HDL-cholesterol $>$ 60 mg/dl. *: at the mean value for continuous RFs, and at the reference class for categorical variables. 20-year risk: $1 - S_0(20)^{\exp(\sum \beta X - G(\mu))}$. Calibration slope: correction term to be used in different population to shrink the beta-coefficients. See reference [25] for more details. The risk model should be used within the following range for continuous risk factors: total cholesterol 135-330 mg/dl; HDL-cholesterol 30-100 mg/dl; systolic blood pressure 100-190 mmHg.

Figure S1: Calibration plot for the final 20-year risk model. Men (left) and women (right), 35 to 69 years old, free of CVD at baseline.





Figure S2: Distribution of predicted 10-year and 20-year risk of first major CVD event, according to the number of risk factors. Men (left) and women (right), 35 to 49 years old, free of CVD at baseline.



1
2
3 Risk factors stratification derived from Lloyd-Jones [7].

4 All optimal: total cholesterol <180 mg/dl, HDL-Cholesterol \geq 40 mg/dl [men] or \geq 50 mg/dl [women], blood pressure <120/80 mmHg, non smoker, non diabetic;

5 1+ non-optimal: total cholesterol 180 to 199 mg/dl, systolic blood pressure 120 to 139 mmHg, diastolic blood pressure 80 to 89 mmHg, non smoker, non diabetic

6 1+ elevated: total cholesterol 200 to 239 mg/dl, systolic blood pressure 140 to 159 mmHg, diastolic blood pressure 90 to 99 mmHg, non smoker, non diabetic

7 Major risk factor: total cholesterol \geq 240 mg/dl, HDL-Cholesterol <40 mg/dl [men] or <50 mg/dl [women], systolic blood pressure \geq 160 mmHg or treatment,
8 diastolic blood pressure \geq 100 mmHg, smoker, or diabetic
9

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only

Table S2: Baseline characteristics of the study population, by study cohort, for risk factors included in the risk prediction model. Men and women, 35 to 69 years old, free of CVD at baseline.

	Cohort study name			
	MONICA 1	MONICA 2	PAMELA	MONICA 3
Recruitment period	1986-87	1989-90	1990-93	1993-94
Number of subjects	1259	1255	1442	1291
Age, years	49.4 (8.6)	49.6 (8.8)	52.5 (9.8)	50.3 (8.7)
Men, %	48.0	49.2	49.9	49.0
Total cholesterol, mg/dl	216.5 (43.3)	215.7 (42.7)	228.6 (42.3)	229.9 (41.7)
HDL-cholesterol, mg/dl	55.5 (14.4)	56.2 (14.6)	55.9 (15.9)	57.1 (15.1)
Systolic Blood Pressure, mmHg	136 (20)	132.3 (19.3)	133.6 (20)	130.6 (19.7)
Anti-hypertensive treatment, %	11.0	13.7	17.6	12.8
Current smokers, %	30.7	27.5	28.3	26.3
Diabetes, %	6.4	6.5	4.4	4.3

Data are mean values (SD) for continuous variables, and % for dichotomous risk factors.




Figure 1: Decision curve for the 20-year risk prediction model in the CAMUNI population, Northern Italy. Men (left) and women (right), 35 to 69 years old, free of CVD at baseline.

Net Benefit: $(TP - w \cdot FP) / n$, where TP = True Positive; FP = False Positive; $w = (\text{Absolute risk threshold}) / (1 - \text{Absolute risk threshold})$; $n = \text{sample size}$

Number of risk factors: total cholesterol >240 mg/dl; HDL-cholesterol <40 [men] or <50 [women] mg/dl; systolic blood pressure >160 mmHg; smoking; diabetes

180x120mm (300 x 300 DPI)

only

1 **Supplementary material for the paper:**

2 **Long-term prediction of major coronary or ischemic stroke event in a low-incidence**

3 **European population: model development and evaluation of clinical utility.**

4 STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

5

6

7

8

9

	Item No	Recommendation	Actions
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	The study setting is clearly stated in the abstract.
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Done
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	See the introduction section at pages 3-4
Objectives	3	State specific objectives, including any prespecified hypotheses	See page 4, end of introduction section
Methods			
Study design	4	Present key elements of study design early in the paper	See the Methods section (pages 4-7)
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Relevant information on cohorts setting, location and periods of recruitment are provided in the paragraphs "Study population" (page 4), "Baseline assessment of risk factors" (page 4) and "Study endpoint and follow-up procedures" (page 5).
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	See the paragraphs "Study population" (page 4) and "Study endpoint and follow-up procedures" (page 5).
		(b) For matched studies, give matching criteria and number of exposed and unexposed	Not applicable
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	See the paragraph "Statistical analysis", page 6-7
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	See paragraphs "Baseline assessment of risk factors" (page 4), and "Statistical analysis" (page 6-7). Exposure group: not applicable for this analysis.
Bias	9	Describe any efforts to address potential sources of bias	See the Methods section.
Study size	10	Explain how the study size was arrived at	See the first period in the "Results" section (page 7)
Quantitative	11	Explain how quantitative variables were	See the "Statistical Analysis" paragraph

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

1	variables		handled in the analyses. If applicable, (page 6)
2			describe which groupings were chosen and
3			why
4	Statistical methods	12	
5			(a) Describe all statistical methods, including See the “Statistical Analysis” paragraph
6			those used to control for confounding (page 6)
7			(b) Describe any methods used to examine See the “Statistical Analysis” paragraph
8			subgroups and interactions (page 6)
9			(c) Explain how missing data were addressed See the first line in the “Results” section
10			(page 7)
11			(d) If applicable, explain how loss to follow- See the “Statistical Analysis” paragraph
12			up was addressed (page 6) for details on the survival analysis
13			techniques
14			(e) Describe any sensitivity analyses Not applicable
15			
16			
17	Results		
18	Participants	13*	
19			(a) Report numbers of individuals at each Participation rates are reported in the
20			stage of study—eg numbers potentially paragraph “Study population” (page 4).
21			eligible, examined for eligibility, confirmed Exposure group: not applicable for this
22			eligible, included in the study, completing analysis.
23			follow-up, and analysed
24			(b) Give reasons for non-participation at each Not applicable
25			stage
26			(c) Consider use of a flow diagram Not applicable
27			
28	Descriptive data	14*	
29			(a) Give characteristics of study participants See Table 1. Exposure group: not
30			(eg demographic, clinical, social) and applicable for this analysis.
31			information on exposures and potential
32			confounders
33			(b) Indicate number of participants with See the “Results” section, first period
34			missing data for each variable of interest (page 7). Exposure group: not applicable
35			for this analysis.
36			(c) Summarise follow-up time (eg, average “Results” section, second period (page 7).
37			and total amount) Exposure group: not applicable for this
38			analysis..
39			
40	Outcome data	15*	
41			Report numbers of outcome events or Number of events, by type, are reported in
42			summary measures over time Table 1. Exposure group: not applicable
43			for this analysis.
44	Main results	16	
45			(a) Give unadjusted estimates and, if The study model is reported in Table S1,
46			applicable, confounder-adjusted estimates and supplementary material; the analysis is
47			their precision (eg, 95% confidence interval). multivariable by nature.
48			Make clear which confounders were adjusted
49			for and why they were included
50			(b) Report category boundaries when Not applicable
51			continuous variables were categorized
52			(c) If relevant, consider translating estimates Not applicable
53			of relative risk into absolute risk for a
54			meaningful time period
55			
56	Other analyses	17	
57			Report other analyses done—eg analyses of Not applicable
58			subgroups and interactions, and sensitivity
59			analyses
60			

Discussion			
Key results	18	Summarise key results with reference to study objectives	See the first part of the Discussion section, page 9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Study limitations are reported and discussed at pages 11-12.
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Done
Generalisability	21	Discuss the generalisability (external validity) of the study results	See pages 11-12
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Source of funding is reported at page 12.

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.